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The Central Nervous System (CNS) consists of neuron and glial cells which 
include astrocytes, oligodendrocytes and microglia. Microglia, while 
traditionally known as the “immune cells” of the CNS are now known to 
possess multiple effector functions ranging from immune surveillance, 
synaptic plasticity and pruning to playing roles in higher order functions such 
as learning and memory. As part of their immune effector function, microglia 
continuously scan the surrounding brain parenchyma for perturbations 
resulting from injury or other pathological conditions. Upon stimulation in 
pathological conditions, microglia undergo morphological and functional 
changes, become activated, migrate to the site of injury and release several 
cytotoxic molecules such as  superoxides, nitric oxide (NO), reactive oxygen 
species (ROS), proinflammatory cytokines and chemokines. However, in 
neuropathologies including neurodegenerative diseases such as Alzheimer’s 
disease, and Parkinson’s disease, microglia are chronically activated releasing 
excessive amount of the proinflammatory mediators, resulting in exacerbation 
of the neuroinflammation and neuronal damage. Thus, it has been widely 
suggested that understanding the mechanism of microglia-mediated 
inflammation is crucial towards developing neurodegenerative disease 
therapies. 
MicroRNAs (miRNAs) function as epigenetic regulators of gene 
expression by binding to the 3’ UTR of their target mRNAs resulting in gene 
silencing either by mRNA translational inhibition or mRNA degradation. 




mediated pathologies. About 70% of all known miRNAs are expressed by 
human and rodent brains with dynamic changes in their expression pattern 
during development and disease processes. MiRNAs have been shown to 
regulate microglial functions, however a catalogue documenting the altered 
expression of miRNAs in activated microglia is lacking. It is hypothesized that 
microglial activation in neuropathological conditions is regulated by molecular 
and epigenetic mechanisms. In order to understand the altered expression 
profile of miRNAs contributing to microglial activation, a global miRNA 
microarray was carried out using control and activated primary microglia 
(activation by LPS and β-amyloid). This screen identified several differentially 
expressed miRNAs in activated microglia in response to LPS and β-amyloid. 
The microarray was followed by pathway analysis using Ingenuity Pathway 
Analysis (IPA) software for identification of specific pathways targeted by 
selected (up/down regulated) miRNAs. Quantitative PCR analysis was used to 
validate the expression of selected miRNAs from the microarray screen in 
primary and BV2 microglia. In order to understand the miRNA-mediated 
regulation of microglial functions, 2 miRNAs were chosen for further analysis: 
1. miR-27a which was found to be upregulated in activated microglia; 2. 
miRNA-200b which was found to be repressed in activated microglia. 
 MiR-27a was predicted to target SMAD2, TβR1 and Runx1, members 
of the TGFβ signalling pathway in microglia. TGFβ1 is an anti-inflammatory 
cytokine and TGFβ signalling via SMAD2/3 has been shown to lead to 
microglial quiescence. Thus, it was hypothesized that miR-27a promotes the 
proinflammatory response of microglia by suppressing TGFβ-SMAD 




cJun, a member of the mitogen activated protein kinase (MAPK) signalling 
pathway. MAPK pathways regulate production of proinflammatory cytokines 
and cytotoxic molecules by activated microglia. Thus it was hypothesized that 
miR-200b inhibits microglia activation by suppressing the cJun/MAPK 
pathway in microglia. 
 MiR-27a was identified as a novel miRNA upregulated in activated 
primary microglia in vitro as well as in activated microglia isolated using 
laser-capture microdissection from traumatic brain injury (TBI) rat model in 
vivo. Bioinformatic analysis had predicted miR-27a to target the TGFβ 
pathway in microglia. TGFβ1 cytokine was found to be upregulated in 
activated microglia in vivo whereas TGFβ receptor 1 (TβR1) and SMAD2, key 
mediators of TGFβ signalling were found to be downregulated in activated 
microglia in vitro. On the other hand, Runx1, a target of TGF-β- SMAD 
signalling was found to be upregulated in activated microglia. Gain-of-
function, loss-of-function studies using miR-27a mimic and inhibitor 
respectively, confirmed TβR1, SMAD2 and Runx1 as the targets of miR-27a. 
MiR-27a inhibition resulted in an increase in SMAD2 activity as measured by 
the expression of phospho-SMAD2. Further, miR-27a was observed to 
positively regulate the inflammatory response of microglia with 
overexpression of miR-27a resulting in a decrease in the expression of 
alternative activation genes such as Ym1 and Arginase1 and an increase in the 
expression of the proinflammatory cytokines TNFα, IL6, IL-1β and iNOS. 
Furthermore, miR-27a overexpression also resulted in increased NF-κB 
nuclear translocation in microglia, correlating with increased inflammatory 




medium (CM) obtained after overexpression of miR-27a in microglia appeared 
to be neurotoxic as it had a cytotoxic effect on survival of the neurons as 
evidenced by Annexin V FACS analysis. These results demonstrate how 
miRNAs can regulate the expression of specific genes thereby promoting the 
proinflammatory actions of microglia. 
MiR-200b was found to be repressed in activated microglia in vitro as 
well as in activated microglia isolated using laser-capture microdissection 
from traumatic brain injury (TBI) rat model in vivo. MiR-200b was shown to 
target cJun, the substrate of JNK MAPK (mitogen-activated protein kinase) 
which mediates the release of proinflammatory cytokines. Loss-of-function 
and gain-of-function studies using miR-200b inhibitor and mimic respectively, 
in microglia confirmed cJun to be the target of miR-200b. Luciferase assay 
confirmed the binding of miR-200b to the 3’UTR of cJun gene demonstrating 
that cJun is a direct target of miR-200b. Overexpression of miR-200b resulted 
in a decrease in JNK expression and activity, thus dysregulating the MAPK-
JNK pathway. Further, miR-200b was shown to negatively regulate the 
inflammatory response of microglia. Knockdown of miR-200b resulted in an 
increase in the pro-inflammatory cytokines, TNF-α, IL-1β and IL6, as well as 
iNOS expression and NO production. Conversely, overexpression of miRNA-
200b led to a decrease in the pro-inflammatory cytokines, iNOS and NO. 
Furthermore, overexpression of miR-200b impaired the migratory potential of 
activated microglia. Lastly, treatment of MN9D neurons with microglia 
conditioned medium after miR-200b knockdown resulted in increased cell 
death as compared to control as a result of increased secretion of 




In conclusion, this study provides a database of differentially expressed 
miRNAs in activated microglia. Further, the author attempts to understand the 
miRNA regulation of microglial function via 2 differentially expressed 
miRNAs in activated microglia. It is concluded that miRNAs altered different 
aspects of microglial functions including inflammatory response, migration 
and neuronal survival by regulating the TGFβ and MAPK signalling pathways 
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The Central Nervous System (CNS) consists of neurons and non-neuronal 
glial cells. Glia consist of macroglia constituting astrocytes and 
oligodendrocytes and microglia. Microglial cells which account for 5–20% of 
the total glial cell population within the CNS parenchyma are distributed 
throughout the brain and spinal cord (Lawson et al. 1990). Microglia have 
been shown to originate from the yolk sac and populate the CNS prior to 
vasculogenesis (Ginhoux et al. 2010) and are involved in maintaining the 
internal milieu of the CNS in both health and disease (Perry et al. 2010).   
Microglia appear round or amoeboid in shape in early postnatal stage 
and undergo functional and morphological transformation to form “ramified” 
or “resting” microglia in adult stage (Ling and Wong 1993). Resting microglia 
in the adult brain have a small cell body and are highly ramified with multiple 
fine processes. “Resting” is a misnomer because these cells continuously scan 
the surrounding parenchyma with their processes and communicate directly 
with neurons and astrocytes (Davalos et al. 2005; Nimmerjahn et al. 2005; 
Graeber 2010). This perpetual state of motion allows them to respond swiftly 
to neuronal damage or infection by transforming into an activated phenotype 
and performing inflammatory functions. They are remarkably plastic and 
capable of responding to a vast array of challenges in the CNS. Upon detection 
of specific factors generated by parenchymal injury, degeneration, or infection, 
microglia undergo morphological transformations and respond rapidly through 
induction of genetic programs designed to overcome and repair CNS insults 




function are observed during almost all neuropathological conditions (e.g., 
degenerative diseases, infection, stroke, tumors and brain injury) (Banati and 
Graeber 1994; Stoll and Jander 1999; Streit et al. 1999). Initially thought to be 
the immune effectors of the CNS, microglia are now known to perform several 
neurological functions including regulation of synaptic activity (Nayak et al. 
2014). Thus, microglia play a major role in maintaining the overall health of 
the CNS. 
 
1.1 Microglia Origin and Development 
Neurons, astrocytes and oligodendrocytes arise from the neuroectoderm during 
embryogenesis. However, microglia are distinct from the other CNS cell types 
as they have been shown to originate from the mesoderm.  
Although microglia were believed to have neuroectoderm origin in 
early days, their non-neuroectodermal origin was first suggested in 1932 
(Rezaie and Male 2002). Subsequently, it was shown that the precursor cells 
of monocyte lineage or the circulating monocytes enter brain during the 
embryonic, fetal or postnatal stages of development and differentiate into 
microglia (Ling and Wong 1993; Kaur et al. 2001). Recent in vivo fate 
mapping study of yolk-sac-derived cells in mice revealed that microglia are 
derived from extra embryonic yolk sac macrophages that populate the brain 
during early fetal development (Ginhoux et al. 2010). This finding was further 
confirmed by Schulz and his colleagues, since the transcription factor Myb, 
which is required for hematopoiesis and the generation of hematopoietic stem 
cells (HSCs), was found to be not essential for the generation of microglia 
(Schulz et al. 2012). Myb
−/−




monocytes/macrophages but had normal numbers of microglia in the CNS, 
indicating that yolk sac-derived macrophages are distinct from HSC derived 
progeny. Further studies revealed that microglia are derived from CD45
-
/c-
kit+ erythromyeloid progenitor cells (Kierdorf et al. 2013). These precursors 
developed into CD45+/c-kit
low
/CX3CR1− immature cells, which finally 
matured into CD45+/c-kit−/CX3CR1+ microglia and invaded the brain 
rudiment using matrix metalloproteinases (MMPs), such as MMP-8 and 
MMP-9. Collectively, these studies support the concept that microglia are 
derived from embryonic yolk sac. During neonatal development, primitive 
yolk-sac-derived microglial progenitors appear amoeboid. However, they 
eventually progress through a developmental program that includes 
proliferation and subsequent acquisition of ramified processes, which give rise 
to the ramified microglial phenotype commonly observed in the adult CNS 






Illustration 1: Adapted from Nayak et al, 2014 (Nayak et al. 2014). 
 
1.2 Homeostatic functions of microglia 
 
1.2.1 Neurogenesis 
During development there is a need for precise generation of neurons and glia 
(astrocytes and oligodendrocytes) from neural precursors. Interestingly 
microglial precursors have been co-localised in neuroepithelia with neural 
progenitors indicating a role for these cells in neurogenesis (Kaur et al. 2001; 
Chan et al. 2007; Ginhoux et al. 2010). Further, microglia are known to 




growth factor (bFGF), brain-derived neurotrophic factor (BDNF), insulin-like-
growth-factor-1 (IGF-1), which support the formation of neural circuits and 
promote their survival (Yamagata 1995; Tuan Trang, Simon Beggs 2011; 
Ueno et al. 2013) (Illustration 2). 
 
1.2.2 Programmed Cell Death in developing CNS 
Excessive immature neurons formed during development are eliminated 
through programmed cell death (Buss et al. 2006). In addition, neurons that 
form weaker neuronal circuits or that perform only transient functions also 
undergo apoptosis. Microglia initiate this cell death by releasing “death-
inducing factors” and phagocytose the resulting debris (Ueno and Yamashita 
2014) . Several molecular mechanisms by which microglia initiate neuronal 
apoptosis in distinct regions of the CNS have been identified: 1) releasing 
superoxide ions in the cerebellum (Jose Luis Marin-Teva et al. 2004), 2) 
through nerve growth factor in the retina which induces cell death via p75 
neurotrophin receptor (Jose Maria Frade 1998), 3) through TNF in the spinal 
cord (Sedel et al. 2004), 4) through induction of the complement system via 
complement receptor 3 (CR3) in the hippocampus (Schafer et al. 2012).  
In addition to initiating apoptosis, microglia help clean up the CNS 
parenchyma by phagocytising the dead and dying neurons without initiating an 
inflammatory response (Marín-Teva et al. 2011). Non inflammatory 
phagocytosis proceeds through triggering receptor expressed on myeloid cells-
2 (TREM2) signaling (Takahashi et al. 2005). TREM2 signaling activates 
DAP12, a transmembrane immune receptor protein, which induces 




Linnartz et al. 2010). In this manner, both, numbers of neural precursors as 
well as differentiated neurons are regulated by microglia (Cunningham et al. 
2013).  
 
1.2.3 Synaptic pruning  
Microglial phagocytic activity is essential for synaptic homeostasis (Paolicelli 
et al. 2011; Wake et al. 2013). Proper synaptic function is dependent on 
several trophic factors and synaptogenic signals released by microglia. It has 
been demonstrated that DAP12 signaling is essential for synaptic function and 
plasticity (Roumier et al. 2004). In the mouse brain, the expression of DAP12 
is restricted to microglia. Loss of DAP12 leads to reduction of tyrosine kinase 
receptor B (TRK-B), a receptor for brain-derived neurotrophic factor (BDNF), 
leading to aberrant synaptic function. Further, studies on ex-vivo organotypic 
hippocampal slice cultures revealed that microglia can influence synaptic 
function by regulating synaptic densities and dendritic spine numbers (Ji et al. 
2013). Microglial engulfment of pre- and post-synaptic proteins has also been 
observed (Paolicelli et al. 2011). Microglia mediate synaptic pruning via 
CX3CR1 signaling. CX3CR1 is a chemokine receptor expressed solely by 
microglia in the CNS (Hughes et al. 2002; Limatola and Ransohoff 2014). 
CX3CR1 deficient mice show increased dendritic spines thereby indicating 
aberrant synaptic pruning (Paolicelli et al. 2011) (Illustration 2).   
The complement system is also known to mediate microglial synaptic 
pruning. Neurons express the complement protein C1q which activates C3. 
Since microglia express C3 receptor (CR3), it is possible that microglia 




Indeed, mice deficient in C1q or C3 retained excessive synaptic connections 
(Stevens et al. 2007). Moreover it has been shown that microglia phagocytose 
retinogeniculate synapses via CR3 signaling. Collectively these studies 
indicate that microglia participate in synaptic development and maintenance 
(Schafer et al. 2012).  
 
1.2.4 Synaptic maturation 
In addition to synaptic pruning, microglia are required for proper synaptic 
maturation. Around postnatal day 13, as compared to wildtype littermates, the 
amplitude and frequency of miniature excitatory post-synaptic currents 
(mEPSCs) are increased in CX3CR1 null mice (Paolicelli et al. 2011). 
CX3CR1 null mice also display alterations in excitatory transmission (Zhang 
et al., 2014). Since CX3CR1 is expressed solely by microglia in the CNS, 
these studies are suggestive of a role of microglia in maturation of synapses. 
Consistent with this hypothesis, mice harbouring DAP12 mutation display 





Illustration 2 showing the regulation of neurogenesis and synaptic maturation 




1.2.5 Synaptic plasticity involved in learning and memory in the adult 
Synaptic plasticity involves activity-triggered persistent changes in synaptic 
efficacy and is the fundamental mechanism underlying learning and memory. 
Such persistent activity-triggered synaptic inputs may result in an increase or 
decrease in synaptic efficacy referred to as long-term potentiation (LTP) or 
long-term depression (LTD) respectively. Learning and memory is dependent 
on neurogenesis, which occurs in the developing and adult brain. Microglia are 
regulators of activity-driven synaptic plasticity (Rogers et al. 2011; Schafer et 
al. 2013), adult neurogenesis (Gemma and Bachstetter 2013) and learning and 
memory (Rogers et al. 2011; Tremblay 2011; Parkhurst et al. 2013). Microglia 
through CR3 affect activity independent LTD (J. Zhang et al., 2014).  CNS-




with reduced LTP but increased LTD at the Schafer collateral-CA1 synapses 
in the hippocampus (Butovsky et al. 2014). These observations are consistent 
with those in CX3CR1 null mice in which LTP is almost eliminated with the 
mice displaying deficits in hippocampal-dependent learning and memory 




 mice (transgenic mice in 
which a selected depletion of microglia is possible) it has been observed 
(Parkhurst et al. 2013) that microglia-depleted mice showed deficits in 
contextual fear conditioning, novel object recognition, tests of hippocampal 
dependant learning and motor learning. In addition, reduction in both 
elimination and formation of dendritic spines was observed in microglia-
depleted animals, indicating the essential role of microglia in synaptic 
plasticity and learning in the normal adult CNS. Further, it has been shown 
BDNF, a neurotrophin known to regulate synaptic plasticity (Korte et al. 
1995) is expressed in microglia which regulate learning and memory through 
BDNF signaling (Parkhurst et al. 2013). 
 
1.3 Activation of microglia 
 
1.3.1 Different activation states of microglia 
In response to different stimuli, microglia and peripheral macrophages are 
known to display different reactive phenotypes.  These activation states are 
broadly classified into 2 types: 
M1/Classical activation: Activation of microglia and macrophages in 




proinflammatory cytokines and an enhanced microbicidal capacity is defined 
as the M1 or classical activation phenotype. Interferon- (IFN) and LPS 
trigger an M1 phenotype in microglia which are characterized by a high 
expression of TNFα, Toll-like-receptors (TLRs), co-stimulatory molecules for 
antigen presentation and cytotoxic molecules like reactive oxygen species 
(ROS). The M1 phenotype has been shown to be neurotoxic (Boche et al. 
2013). This classical activation of microglia has been clearly demonstrated in 
a number of neuropathologies such as experimental autoimmune 
encephalomyelitis (EAE)-induced demyelination, and neurodegenerative 
diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and 
amyotrophic lateral sclerosis (ALS) (Colton 2009; Luo and Chen 2012). 
M2/Alternative activation: M2 phenotype in microglia is defined as the 
response elicited in response to cytokines, interleukin-4 (IL-4) or interleukin-
13 (IL-13) and is characterized by the expression of anti-inflammatory 
cytokines such as interleukin-10 (IL-10) and TGF and high expression of 
scavenger receptors such as RAGE and CD36 (Aguzzi et al. 2013). Thus this 
phenotype microglia are neuroprotective as they exert anti-inflammatory 
effects, resolve inflammation and promote tissue repair (Hanisch 2013). It has 
been observed that in vitro stimulation of microglia with anti-inflammatory 
cytokines induced expression of alternative activation genes such as arginase 1 
(Arg1), mannose receptor, found in inflammatory zone I (FIZZ1) and chitinase 
3-like protein 3 (Ym1) (Colton 2009). Microglia and peripheral macrophages 
have also been shown to switch from one phenotype to another influencing the 




microglia assume a M1 phenotype and switch to M2 as the response matures 
(Hanisch and Kettenmann 2007).  In an oxygen-glucose deprivation model 
(OGD), M1 primed microglia aggravated neuronal cell death while M2 primed 
microglia enhanced neuronal survival (X. Hu et al., 2012). In EAE, the mouse 
model of multiple sclerosis, microglia were found to be exclusively M2 
primed as evidenced by the expression of YM1. Further, infiltrating 
macrophages were also positive for Ym1 (Ponomarev et al. 2007).  
A third activation phenotype has been proposed, M3, with IL-10 and 
TGF being the inducers of this phenotype. While direct evidence supporting 
the existence of this phenotype in microglia is lacking, it should however be 
noted that delivery of IL-10 in APP/PS1 mice (transgenic mouse model of AD 
with apolipoprotein mutation) has been shown to reduce 
astrogliosis/microgliosis, increase neurogenesis and restore spatial learning 
abilities (Kiyota et al. 2012). Further, TGF has been shown to enhance the 
anti-inflammatory effects of IL-4 including induction of Arg1 and YM1, the 
alternative activation markers in microglia in vitro. Moreover blocking of the 
TGF receptor 1 (TβR1) resulted in a reduction of Arg1 and YM1 in microglia 
(Zhou et al. 2012) suggesting that TGF enhances IL-4 mediated 
M2/Alternative activation in microglia. These results point towards the 
presence of a third “deactivated” state of microglia with microglia returning to 
the same functional state as the resting phenotype. This “deactivated state” 
may be genetically and/or epigenetically different from the native/resting state 






In early postnatal period, amoeboid microglia undergo rapid proliferation and 
develop into mature ramified microglia. Only about 30% of the total amoeboid 
microglia transform into ramified form with the rest undergoing apoptosis 
(Imamoto and Leblond 1978; Ling and Wong 1993). In order to document the 
molecular changes governing microglial transformation, a microarray analysis 
performed using laser capture microdissected microglia from 5 day and 28 day 
rat brain revealed several genes involved in cell proliferation to be highly 
expressed in amoeboid microglia (Parakalan et al. 2012). Runx1t1 (Runt-
related transcription factor 1, translocated to 1), a gene found to be expressed 
in amoeboid microglia from this microarray, has been established as a novel 
transcriptional repressor of microglial proliferation (Baby et al. 2014). Further,  
Runt-related transcription factor 1(Runx1) has been identified as a regulator of 
transformation of amoeboid microglia into ramified microglia by controlling 
microglial proliferation in early postnatal stage in vivo (Zusso et al. 2012).  
Further, Runx1 has been shown to be induced in adult microglia during nerve 
injury (Zusso et al. 2012) and traumatic brain injury (Logan et al. 2013) to 
control microgliosis occurring as a result of microglial proliferation.  
Microglia have been shown to undergo rapid proliferation in several 
CNS pathologies. In human brain from AD patients, proliferating microglia 
were observed. Further, it occurred in close proximity of plaque pathology, 
and may contribute to the neuroinflammation common in AD (Marlatt et al. 
2014). In another neurodegenerative disease, incidental Lewy body disease 
(iLBD), a prodromal state of PD, increased number of proliferating microglia 




However, proliferating microglia were not observed in established PD patients 
suggesting an early microglial response to developing PD pathology (Doorn et 
al. 2014).  Using immunohistology and in vivo two-photon imaging, rapid 
proliferation of the resident microglia was detected around the ischemic core 
of the stroke brain. Further reactive microglia were also recruited to the 
ischemic area continuously during the first week after stroke induction (T. Li 
et al., 2013).  
A number of receptors expressed by microglia are known to play a role 
in microglial proliferation. An important molecule governing microglial 
proliferation is CSF1R, the receptor for colony stimulating factor (CSF). 
CSF1R is solely expressed by microglia in the CNS. CSF1 is upregulated in 
the AD brain and promotes the proliferation of microglia by binding to the 
CSF1R (Erblich et al. 2011).  
 
1.3.3 Phagocytosis 
Phagocytosis is an important function of microglia enabling it to clear cellular 
debris in healthy and diseased conditions. The mechanism of phagocytosis by 
microglia is relatively unknown. However recent studies suggest a three step 
process of phagocytosis by microglia: “find-me”, “eat-me” and “digest-me” 
(Sierra et al. 2013) (Illustration 3). 
1. Find-me: when the motile processes of microglia encounter signals 
released by a target (dying neurons or infective pathogens), the 
phagocytosis process is initiated. For example, uridine diphosphate 
(UDP), acts on P2Y6 receptors on the microglial surface to facilitate 




fractalkine receptor/CX3CR1 which binds to its ligand 
fractalkine/CX3CL1 released by apoptotic cells which promote their 
phagocytosis (Noda et al. 2011). 
2. Eat-me: depending on their targets, phagocytes such as microglia, 
express two types of cell surface receptors enabling them to recognise 
distress signals from either invading pathogens or apoptotic cells 
(Ravichandran 2010). Phosphatidylserine (PS), which is a component 
of cellular membrane and is expressed on apoptotic cell membrane, is 
the most distinguished “eat me” signal (Ravichandran 2010). Microglia 
express various P2X and P2Y receptors, nucleotide receptors, which 
regulate phagocytosis and are also considered as “eat me” signal 
(Franke et al. 2007; Koizumi et al. 2007). Another important receptor 
that signals internalization is TREM2, whose loss-of-function prevents 
microglial phagocytosis (Takahashi et al. 2005). In order to initiate 
phagocytosis, microglia express various receptors including 
lipopolysaccharide (LPS) receptor, CD14 (Reed-Geaghan et al. 2009), 
the scavenger receptor, CD36 and the toll-like receptors (TLRs) (Yu 
and Ye 2014). In addition to direct recognition of target by microglia 
receptors, antibodies such as IgG and complement proteins such as C3 
can also bind to Fc receptors and complement receptors (CR3) 
respectively, present on microglial cell surface, triggering 
internalization. Microglia have also been shown to phagocytose weaker 
synapses and dendrites via CX3CR1 and CR3 mediated mechanisms 




3. Digest-me: a number of hydrolytic enzymes such as cathepsins, ATP 
proton pumps to acidify the medium, are required for degradation of 
the internalized target (Garin et al. 2001). A live-cell imaging study in 
Caenorhabditis elegans has revealed that nematode microglia possess 
ATP proton pumps for target degradation (Peri and Nüsslein-Volhard 
2008). Further, phagocytosis is not limited to amoeboid or activated 
microglia alone, but is carried out by ramified microglia as well (Peri 
and Nüsslein-Volhard 2008; Sierra et al. 2010).  
 
 
Illustration 3 Adapted from Sierra et al, 2013 (Sierra et al. 2013). 
 
 
1.3.4 Production of cytokines and chemokines 
Cytokines are signaling molecules produced by a cell for specific biological 
functions. Microglia are known to secrete several cytokines including IL6, IL-
1β, TNFα, TGFβ, IL-10 and CSFs (Benveniste 1992). Microglia release 
cytokines which in turn activate microglia as a part of their immune response 
in the CNS (Hanisch 2002). Several exogenous factors including viral envelop 
protein, bacterial cell wall components such as LPS, bacterial DNA, and 
prions stimulate the release of cytokines by microglia (Heppner et al. 2001). 




factors, complement proteins or disturbance in ATP or K
+
 levels (Hanisch 
2002).  
Cytokines are of two types- pronflammatory- or anti-inflammatory 
(Benveniste 1992). As the name suggests proinflammatory cytokines including 
IL6, IL-1β, and TNFα aid in the activation of microglia and peripheral 
macrophages in inflammatory conditions (Benveniste 1992; Merrill 1992) . 
Anti-inflammatory cytokines include TGFβ, and IL-10 and are released in 
order to reduce inflammation and assist in tissue growth and repair (Hanisch 
2002). The cytokine, IFN- is a well-known inducer of antimicrobial, pro-
inflammatory, and antigen-presenting functions of microglia (Benveniste 
1992).  Upon activation of microglia, IFN- binds to its receptor which is 
readily expressed in microglia (Vass and Lassmann 1990). This activates the 
transcription factor STAT-1 further activating the downstream target genes 
(Leonard and O’Shea 1998; Nguyen and Benveniste 2000).  
TNF is another pro-inflammatory cytokine, promoting phagocytosis 
and secretion of pro- and anti-inflammatory cytokines by activated microglia 
(ChaoHuShengand Peterson 1995; ChaoHuShengTsanget al. 1995).  TNF is 
a major autocrine activator produced by microglia during CNS inflammation 
(Becher et al. 2000). The TNF receptors, TNFRI and TNFRII have been 
shown to be expressed in microglia in vitro (Dopp et al. 1997). TNFα activates 
several transcription factors including NFkB (Cao et al. 1999) to promote the 
transcription of many immune genes.  
IL-1 is another pro-inflammatory cytokine produced by microglia 




inducing the expression of cytokines (Chao and Peterson 1995) and 
chemokines (McManus et al. 1998). IL-1 can also serve as an autocrine 
activator (Janabi et al. 1996; Saud et al. 2005).  
Microglia produce a number of anti-inflammatory cytokines, such as 
IL-10, TGF (Palin et al. 2001; Rasley et al. 2006), which down-regulate the 
expression of proinflammatory cytokines, chemokines and cytotoxic 
molecules such as ROS (Aloisi et al. 1999; O’Keefe et al. 1999).  
 
Chemokines are small peptides playing crucial role in cell migration 
and cellular communication(Fernandez and Lolis 2002). Chemokines act by 
binding to chemokine receptors expressed on target cells (Rollins 1997). 
Signaling of chemokines through various chemokines receptors present on 
microglial surface is important for microglial proliferation, migration, 
cytoskeletal reorganization and cytokine production (Boddeke et al. 1999; 
Trebst et al. 2003; de Jong et al. 2008). Microglia are known to upregulate 
chemokine receptors during development CXCL1, (Filipovic et al. 2003) as 
well as in neuropathological conditions such as ischemia (CXCL8/IL-8) 
(Popivanova et al. 2003), AD (CCL2/MCP-1) (Ishizuka et al. 1997), multiple 
sclerosis (CCL3/MIP-1) (Balashov et al. 1999) and in different bacterial and 
viral infections (CCL4/MIP-1) (McManus et al. 1998). 
 
1.3.5 Migration 
Migration is an important aspect of microglial function in immune response. 
Ramified microglia sense the contiguous parenchyma using their fine 




and Male 1999). A number of candidate molecules serve as triggers for 
microglial migration including neurotransmitters such as ATP and purinergic 
receptors (P2Y12) (Irino et al. 2008), AMPA and metabotropic glutamate 
receptors (Liu et al. 2009), chemokines such as CCL21 (Rappert et al. 2002), 
CX3CL1 released by neurons which bind to receptors CXCR3 and CX3CR1 
(Liang et al. 2009) on microglia, lysophosphatidic acid (Schilling et al. 2004), 
bradykinin (Ifuku et al. 2007) and β-amyloid (Heneka et al. 2010). In addition, 













 exchanger also play an important role in cell migration (Schwab 
2001). Impaired microglial migration leads to several brain diseases such as 
Prion disease (Ciesielski-Treska et al. 2004), PD (Park et al. 2008) and AD 
(Mizuno 2012) and inhibit axonal regeneration during acute CNS injuries 
(Vargas and Barres 2007). 
 
1.4 Important signalling pathways that regulate microglia 
functions 
 
1.4.1 Mitogen-activated protein kinase (MAPK) pathway  
Mitogen-activated protein kinase (MAPK) signal transduction pathways are 
ubiquitously expressed, highly evolutionarily conserved mechanisms that 
enable cells to respond to a variety of stimuli, thereby regulating cellular 
functions (Kyriakis and Avruch 2012). MAPK pathways coordinate cellular 




protein-coupled receptors and environmental stresses among others (Kyriakis 
and Avruch 2001). Mammals express multiple MAPK pathways with a 
majority of these being triggered by stress and inflammatory stimuli. The three 
major MAPK pathways are the extracellular signal-regulated kinases (ERK 
1/2 or MAPKs1/3 or p44/42), cJun NH2-terminal kinases (JNKs) and p38 
MAPK (Oliver and Jamur 2010). It has been shown that p38 and ERK 
MAPKs regulate the production of TNF and iNOS in LPS activated glial 
cells including microglia and astrocytes (Zhang et al. 1998).  p38 MAPK-
mediated release of TNF and NO was further observed in LPS activated rat 
and human microglia (Lee et al. 2000; Xing et al. 2008). JNK signaling is 
known for promoting cytokine production from LPS-stimulated or hypoxia-
exposed microglia in vitro (Waetzig et al. 2005). Activation of all three 
MAPK cascades has been reported in LPS-stimulated BV2 microglia (Kim et 
al. 2004). In activated BV2 microglia, p38 and JNK pathways are upregulated, 
leading to ROS production via activation of NADPH oxidase (Sun et al. 2008; 
Wang et al. 2011). Moreover, in the rat model of white matter damage induced 
by hypoxia, activation of  microglia was found to be associated with 
upregulation of JNK signaling while inhibition of JNK activation significantly 
reduced neuroinflammation (Wang et al. 2012). In vivo evidence also 
implicates MAPK pathways to aid microglial activation in brain pathologies 
such as stroke and AD. Activated MAPK signaling pathways contribute to AD 
pathogenesis through neuronal apoptosis (Tamagno et al. 2003), 
transcriptional activation of β and γ-secretases (Tamagno et al. 2005) and 




et al. 2009). -synuclein a key protein in the pathogenesis of PD has been 
shown to activate p38, ERK, and JNK pathways in human microglial cells, 
thus inducing inflammation by promoting the production of IL-1β and TNFα 
(Klegeris et al. 2008). The MAPKs have also been implicated in causing 
neuronal death in PD by various other mechanisms such as phosphorylation of 
p53 by p38 MAPK (Chipuk et al. 2008) and activation of JNK (Vila et al. 
2004; Brecht et al. 2005). Further, abberant MAPKs function in motor neurons 
and microglia, (Bendotti et al. 2005). p38 triggers NO production contributing 
to the Fas-dependent apoptosis of motor neurons in ALS (Raoul et al. 2002). 
The above evidence suggests that MAPKs signaling is triggered in activated 
microglia in vivo and in vitro and mediates neuroinflammation via microglial 
activation.  
 
1.4.2 Transforming growth factor beta (TGF-β) pathway 
TGF1 is a pleiotrophic cytokine involved in different biological processes 
including gliosis, inflammation, cell survival and proliferation (Dünker and 
Krieglstein 2000) . TGFβ initiates responses by activating transmembrane 
serine-threonine kinase receptors: I (TRI) and II (TRII) (Massagué 2000). 
The activated TRI then interacts with the SMAD2 and/or SMAD3 
transcription factors (Khalil et al. 2001). After activation by phosphorylation, 
SMAD2 and SMAD3 associate with SMAD4 and translocate to the nucleus to 
activate transcription of target genes (Massagué 2000; Massagué et al. 2005). 
In microglia, TGF1 acts as an anti-inflammatory cytokine having a variety of 
immunomodulatory functions including inhibition of production of 




al. 2013), chemokines (Hu et al. 1999; Paglinawan et al. 2003) and reactive 
oxygen intermediates by microglia (Chao and Peterson 1995; Hu et al. 1995). 
In the ischemic brain, overexpression of TGF1 has been shown to inhibit 
microglial activation and the release of proinflammatory chemokines (Gross et 
al. 1993). Further, TGF1 is induced after Traumatic Brain Injury (TBI) 
presumably to control microglial proliferation and increase neurogenesis 
(Logan et al. 2013).  These data suggest that TGF1 and its signaling 
members and/or target genes could serve as potential targets for therapeutic 
manipulations to control microglia- mediated neuroinflammation in various 
CNS pathologies. 
 
1.5 Regulation of microglia quiescence by extrinsic and 
intrinsic signals 
 
1.5.1 Extrinsic signals 
Under homeostatic conditions, microglia are maintained in “resting” condition 
by a number of CNS parenchymal factors. These environmental signals are of 
two types, “On” and “Off” signals (van Rossum and Hanisch 2004; Hanisch 
and Kettenmann 2007). “On” signals are molecules that trigger microglial 
activation. These molecules include bacterial cell wall components, viral 
RNAs, neurotransmitters and intracellular proteins (Kettenmann et al. 2011). 
These “On” signals molecules are recognised by a number of receptors present 
on microglial cell surface (Kawai and Akira 2010). Damaged neurons secrete 




of “on” signals. These nucleotides are recognised by purinergic receptors 
present on microglia enabling microglial migration and subsequent 
phagocytosis (Koizumi et al. 2007). Excessive glutamate released in 
neurodegenerative conditions also function as ‘On’ signal molecule activating 
microglia (Pocock and Kettenmann 2007).  
 “Off” signals are those that trigger microglia when they are no longer 
received by microglia (van Rossum and Hanisch 2004; Hanisch and 
Kettenmann 2007).  Microglia and neurons interact through cell surface 
molecules such as CD200/CD200R, CD47-SIRPα, CX3XL1/CX3CR1 or 
CD22/CD45 and TREM2b (Hoek et al. 2000; Schmid et al. 2002; Cardona et 
al. 2006; Neumann et al. 2009). Microglia are activated when they no longer 
receive signals from neurons via these receptors. 
 
1.5.2 Intrinsic signals 
Epigenetic factors constitute intrinsic signals regulating microglial activation. 
Recent study has demonstrated that processes involving histone modification 
and noncoding RNAs have important roles in modulating neuroinflammation 
(Garden 2013). It has been demonstrated that acetylation and deacetylation of 
histone proteins regulate the expression of target genes. In general, histone 
acetylation catalyzed by histone acetyl-transferases (HAT) activates gene 
expression by addition of acetyl groups to target proteins whereas histone 
deacetylation catalyzed by histone deacetylases (HDACs) downregulate gene 
expression by removal of the acetyl group from the target protein (Kuo and 




of microglia, whereas HDAC inhibitors (HDACi) influence innate immune 
activity (Kim et al. 2007; Kannan et al. 2013). 
 HDACs are enzymes that catalyze the removal of an acetyl group 
from the target proteins (Kuo and Allis 1998). The effect of HDACi on 
microglial activation is not yet clear.  In some experimental settings, HDACi 
potentiate the inflammatory response of activated microglia, where in other 
studies the opposite effect was observed (Suuronen et al. 2003, 2006; Faraco 
et al. 2009). 
 Recently, microRNAs (miRNAs) have been identified as important 
epigenetic regulators of microglia differentiation and activation. miRNAs are a 
class of small non-coding RNA molecules that either promote degradation 
and/or inhibit translation of their target mRNAs. A discussion on miRNA 
mediated modulation of microglial functions is detailed in subsequent 
sections. 
 
1.6 Microglia in CNS diseases 
 
1.6.1 Microglia in neurodegenerative diseases 
 
1.6.1.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is characterized by 1) neuritic plaques (NPs) 
consisting of -amyloid aggregates, 2) neurofibrillary tangles (NFTs) formed 
as a result of hyperphosphorylation of microtubule-associated protein tau; and 




microglia and astrocytes secrete excessive amount of proinflammatory 
cytokines, IL-1, TNF and IL6, (Lue et al. 2001; Tuppo and Arias 2005), 
further stimulating microglia to produce neurotoxins such as ROS and 
excitatory amino acids, thereby amplifying microglial activation (Giulian 
1999). In culture, in response to  amyloid, microglia produce excessive 
amount of reactive oxygen species, proinflammatory cytokines and 
chemokines (Lue et al. 2001). 
 
1.6.1.2 Parkinson’s disease (PD) 
Loss of dopaminergic neurons in the substantia nigra pars compacts (SN) and 
their projection fibers in the striatum are the characteristic features of PD. 
Microglial phagocytosis of dopaminergic neurons is thought to be an early 
inducer of PD (Kim and Joh 2006). Degenerative dopaminergic neurons 
secrete proteins such as -synuclein, matrix metalloproteinase 3 (MMP-3) and 
neuromelanin. Dopaminergic neurons secrete MMP-3, which activate 
microglia, leading to production of superoxide, TNF, IL6 and  
NO (Wilms et al. 2003; Kim et al. 2005; Zhang et al. 2005; Kim and Joh 
2006).  
 
1.6.2 HIV-associated neuropathology 
The human immunodeficiency virus (HIV) entry into the CNS is mediated via 
the chemokine receptor, CCR5 expressed on the surface of microglia and leads 
to HIV-associated dementia (HAD)  (Moore et al. 2004). The neuronal loss 




Biassette et al. 1999). HAD is characterized by the formation of 
multinucleated giant cell (MNGC). MNGC which form from the fusion of 
microglia and/or macrophages are activated cells and produce excessive 
amounts of ROS and viral proteins (Epstein and Gendelman 1993; Jones et al. 
2000). Further, viral proteins such as, viral HIV-I Tat, gp120 and Vpr 
stimulate inflammation and associated neuronal damage (Ghafouri et al. 
2006). 
 
1.6.3 Brain Injury  
Brain injury refers to mechanical disruption of brain tissue. Neuronal loss 
accompanying brain injury may be a result of direct mechanical threat to the 
brain or due to indirect secondary mechanisms (McIntosh et al. 1998; Stoica 
and Faden 2010). A strong inflammatory response involving microglia is 
mounted after brain injury (Morganti-Kossmann et al. 2007; Kumar and Loane 
2012; Schwarzmaier and Plesnila 2014). Activated microglia are known to 
persist in animal models of brain injury for upto a year after injury (Smith et 
al. 1997; Nagamoto-Combs et al. 2007). Furthermore, the presence of 
activated microglia was observed in patients of brain injury up to 17 years 
after injury, indicating a chronic inflammatory state (Ramlackhansingh et al. 
2011). The role of microglia in brain injury may be both neuroprotective and 
neurotoxic. Microglia, in regions distant from the injury site are known to 
secrete BDNF, which helps in neuronal growth and survival (Nagamoto-
Combs et al. 2007). However, chronic activation of microglia leads to 
production of reactive oxygen species (ROS) in the injured CNS, thereby 






Glioma is a form of brain tumor consisting of tumor cells and a variety of 
immune cells including microglia or macrophages (Graeber et al. 2002). 
Several studies demonstrated that the glioma microenvironment converts the 
glioma-associated microglia into glioma-supportive cells (Ghosh and 
Chaudhuri 2010). Glioma-conditioned medium has also been shown to 
activate microglia in a form that is distinct from the inflammatory phenotype. 
Glioma associated activation leads to the upregulation of metalloprotease 2, 
IL-10 and VEGF from microglia (Markovic et al. 2005; Sliwa et al. 2007; Li 
and Graeber 2012). However, it does not lead to production of 
proinflammatory cytokines. Further, glioma cells secrete TGFβ to maintain 




MicroRNAs are small nonprotein-coding RNA molecules ranging from 18-22 
nucleotides that act as important regulators of post translational gene 
expression (Kim and Nam 2006). MicroRNAs (miRNAs) influence gene 
function by targeting the 3’UTR of mRNAs, thus leading to mRNA 
degradation and the subsequent inhibition of protein translation (Mattick 2009; 
Taft et al. 2010). Typically, a miRNA can bind to several target mRNAs and 
conversely one mRNA can be targeted by several miRNAs (Pasquinelli 2012). 




also play a role in disease pathogenesis and progression (Bartel 2009; Fabian 
and Sonenberg 2012). This highlights the potential of miRNAS as therapeutic 
targets and diagnostic tools (Noori-daloii and Nejatizadeh n.d.; Garzon and 
Marcucci 2012). Recent years have witnessed considerable amount of research 
interest in studies on miRNA-mediated modulation of gene function during 
neuroinflammation (Thounaojam et al. 2013). However, changes in miRNA 
expression occurring during microglial activation in pathological conditions 
have not been documented on a genome wide scale till date and should be the 
focus of future research.  
 
1.7.1 Mechanism of action of miRNA 
The miRNA is loaded onto a RNA-induced silencing complex (RISC), which 
mediates the degradation of target mRNAs. MicroRNAs direct the RISC to 
downregulate gene expression by either of two post-transcriptional 
mechanisms: 1) Degradation of target mRNA 2) Translational repression. The 
bases 2-8 of a miRNA are known as the “seed sequence” of the miRNA 
(Ameres and Zamore 2013). Interaction between this seed sequence and the 3’ 
untranslated region (UTR) of the target mRNA negatively impacts its protein 
output. The strength of this interaction determines if the mRNA will be 
degraded or undergo translational repression due to destabilization of its 
structure (Pasquinelli 2012; Ameres and Zamore 2013).  
 
1.7.2 Identifying mRNA targets of miRNAs 
A number of computational tools predicting putative mRNA targets of 




(Min and Yoon 2010). Among the popular algorithms are miRanda, 
Targetscan, PicTar, PITA and miRWALK.  
1.7.2.1 miRanda 
The miRanda algorithms include the following parameters (Enright et al. 
2003; John et al. 2004): 1) an alignment score for complementarity between 
the seed sequence of the miRNA and the 3’UTR of target mRNA 2) 
determining the degree of conservation between seed sequence of miRNA and 
3’UTR of target mRNA for human and rodents.  
1.7.2.2 Targetscan 
Targetscan includes the following parameters for miRNA target prediction 
(Lewis et al. 2003): 1) an alignment score for complementarity between the 
target mRNA 3’UTR and miRNA seed sequence; 2) presence of a adenosine 
nucleotide at position 1 and/or a Watson-Crick (W-C) match at the eighth 
position, 3) AU content ~30 nucleotides on either sides of the targeted site, as 
well as the target’s distance from the end of the 3’UTR; and 4) degree of 
conservation between target mRNA 3’UTR and miRNA seed sequence for 
different species including human, mouse, rat dog and chicken.  
1.7.2.3 PicTar 
PicTar prediction is based on (Grün et al. 2005) 1) perfect complementarity 
between the seed sequence of the miRNA and the 3’UTR of target mRNA at 
position 1–7 or 2–8. 2) binding energy of the miRNA-mRNA duplex and 3) 
the degree of conservation between seed sequence of miRNA and 3’UTR of 
target mRNA for a number of species including human, mouse, rat dog, 





PITA (Probability of Interaction by Target Accessibility) considers a very 
important criterion overlooked in the above-mentioned programs during 
miRNA target prediction that is, the accessibility of the target site (Kertesz et 
al. 2007). Target sites that are embedded in a closed stem or secondary 
structures are inaccessible to the miRNA RISC complex. PITA provides 
probability of interaction by first checking the seed sequence complimentarity 
with the target mRNA 3’UTR as the other algorithms. This is further followed 
by calculating the energy required to unwind any secondary structures and 
substracting it from the free binding energy to provide a final value of the 
probability of interaction.  
1.7.2.5 MiRWalk 
Apart from the above mentioned bioinformatic programs, miRWalk is a very 
popular and useful tool of choice for miRNA target prediction (Dweep et al. 
2011).  MiRWalk boasts the following features: 1) predicts miRNA binding 
sites on the complete sequence of all known genes of human and rodents 2) 
presents the results together with those from 8 different prediction programs 
including miRanda, PITA and Targetscan among others. 3) provides 
information on both predicted and experimentally validated targets along the 
references. The validated target database is updated every month to 
incorporate any new information. 4) provides information on experimentally 






1.7.3 MiRNAs in the brain 
The nervous system expresses most of the known miRNAs (around 70%) of 
all known miRNAs (Fineberg et al. 2009). They are involved in neuronal cell 
formation, differentiation, brain patterning and their dysregulation is shown to 
contribute to a number of neuropathologies (Follert et al. 2014). However, 
very few microRNAs are expressed in a brain specific or brain-enriched 
manner (Nowak and Michlewski 2013). Along with miRNAs, miRNA 
biogenesis enzymes are also important for brain development. Several brain 
abnormalities have been documented in Dicer deficient mice and mouse model 
of schizophrenia (Stark et al. 2008). MiR-9 and miR-124 are brain-specific 
miRNAs with extensive roles in neurogenesis. MiR-9 has been shown to 
regulate both neural progenitor proliferation and differentiation (Delaloy et al. 
2010; Shibata et al. 2011).  MiR-124 is mostly expressed in post-mitotic 
neurons (Åkerblom et al. 2012) with increase in expression during brain 
development (Sempere et al. 2004).   MiR-124 targets several genes to 
regulate neurogenesis (Cao et al. 2007; Visvanathan et al. 2007). In addition, 
miR-124 regulates neuronal maturation (Rajasethupathy et al. 2009; Gu et al. 
2014), synaptic transmission and cognition (Yang et al. 2012; Wang et al. 
2013). Several miRNAs such as miR-132/miR-212 (Edbauer et al. 2010; 
Magill et al. 2010), miR-134 and miR-138 (Schratt et al. 2006) have also been 
reported to play roles in adult neurogenesis, synaptic plasticity and LTP. 
 
1.7.4 MiRNAs and microglia 
Recent years have witnessed considerable amount of research interest in 




neuroinflammation (Thounaojam et al. 2013). Several miRNAs have been 
shown to target mRNAs influencing microglial functions, thereby modulating 
microglial mediated inflammatory response. A genome wide miRNA 
expression screen to identify differentially expressed miRNAs in the four cell 
types in the CNS, namely: neurons, astrocytes, oligodendrocytes and microglia 
using rat primary culture identified several miRNAs such as miR-126, miR-
146a and miR-150 specifically enriched in microglia as compared to the other 
cell types in the brain (Jovičić et al. 2013). These findings suggested that there 
exist a specific subset of miRNAs enriched in microglia distinct from the other 
neuroglial subtypes presumably to regulate microglial functions in the CNS. 
 
1.7.4.1 MiRNAs in microglia development 
CEBPα, PU.1, Runx1 and M-CSF are required for differentiation of peripheral 
macrophages and microglia development (Nayak et al. 2014).  Recently, miR-
124, a brain enriched miRNA has been shown to be essential in maintaining 
quiescent state of microglia  (Ponomarev et al. 2011).  MiR-124 reduced cell 
proliferation by targeting the cyclins CDK4 and CDK6. Further, miR-124 
targeted the transcription factor CEBPα to reduce expression of its 
downstream targets PU.1 and M-CSF receptor leading to differentiation of 
macrophages to adult microglia in the brain. Further, amoeboid microglia 
(isolated from 5-day old mice pups) exhibited low miR-124 expression level 
along with high CD45 and MHC II expression levels, indicating active 
proliferative state of microglia (Ponomarev et al. 2011, 2013). Ramified 
microglia in the adult brain, on the other hand displayed high miR-124 




significantly downregulated in activated microglia during experimental 
autoimmune encephalomyelitis (EAE) and knockdown of miR-124 in 
microglia resulted in a transformation of these cells from a resting to an 
activated state in vitro and in vivo. These results indicate that miRNAs are 
involved in the 1) formation of microglia by targeting key transcriptions 
factors such as CEBPα and PU.1, 2) transformation of microglia from 
amoeboid to resting ramified state and 3) transformation of adult resting 
microglia to activated form in neuropathology (Ponomarev et al. 2011).  
 
1.7.4.2 MiRNAs in microglia activation 
MiRNAs are now known to influence the polarization of microglia and 
peripheral macrophages towards either the M1 or M2 phenotype (Illustration 
4). Commonly known as a proinflammatory miRNA, the expression of miR-
155 is upregulated in microglia and peripheral macrophages in response to 
several proinflammatory stimuli, such as LPS, IFNγ, and TNFα (Wang et al. 
2010; Bala et al. 2011; Cardoso et al. 2012). Recently miR-155 has been 
shown to target M2-associated genes, such SMAD2 (Louafi et al. 2010), and 
CEBPα, a transcription factor important for the expression of IL-10, arginase 
1, and CD206 (Ruffell et al. 2009), further supporting the hypothesis that miR-
155 can influence the activation of microglia towards M1-like phenotypes. 
Similarly, LPS-responsive miR-27a/b was identified as an M1 polarizing 
miRNA in human monocyte-derived macrophages (Graff et al. 2012). MiR-
27a/b targets the anti-inflammatory cytokine IL-10 and peroxisome 
proliferator-activated receptor  (PPAR), the nuclear hormone receptor, 




macrophages.  MiR-27a overexpression results in an increase in 
proinflammatory cytokines, thereby polarizing macrophages towards the M1 
phenotype (Jennewein et al. 2010; Xie et al. 2014).  Further, miR-27a has also 
been shown to repress members of the TGF pathway, Runx1 and SMAD2 
thereby reducing inflammation and helping polarize microglia to M1-like 
phenotype (Feng et al. 2009; Bao et al. 2014). Recently miR-27a was 
identified in a miRNA microarray screen carried out in activated primary 
microglia (Jadhav SP et al, unpublished data) indicating a role for miR-27a in 
microglia activation and polarization. Several other miRNAs such as miR-101 
and miR-125b have been shown to play a role on the M1-polarization of 
microglia and peripheral macrophages (Zhu et al. 2010; Chaudhuri et al. 
2011). MiR-101 was observed to be upregulated in response to several TLR 
ligands in peripheral macrophages (Zhu et al. 2010). Further, by targeting and 
downregulating MAPK phosphatase 1 (MKP-1), miR-101 mediated the 
activation of MAPK and expression of proinflammatory cytokines in 
peripheral macrophages. Another miRNA, miR-125b targeted interferon 
regulatory factor 4 (IRF4) and mediated the upregulation of MHC class II, 
CD40, CD80, and CD86, thereby bringing about the polarization of peripheral 
macrophages towards the M1 phenotype (Chaudhuri et al. 2011). On the other 
hand, miRNAs -200b and -92a were recently shown to be downregulated in 
microglia and peripheral macrophages respectively, in response to activation 
by TLRs such as LPS. Overexpression of miR-200b in microglia inhibited the 
cJun/MAPK-mediated release of proinflammatory cytokines and NO in 
activated microglia (Jadhav SP et al. 2014). Similarly, miR-92a targeted 




pathway in peripheral macrophages thus contributing to the M1 phenotype 
(Lai et al. 2013). Recently, miR-124 has been reported to contribute to the M2 
phenotype of peripheral macrophages and microglia (Ponomarev et al. 2013). 
Treatment of microglia and peripheral macrophages with cytokines IL-4 and 
Il-13 which are M2 phenotype inducing stimuli, resulted in an upregulation of 
miR-124 expression. Further miR-124 expression contributed to the 
expression of the M2 markers TGF, arginase-1 and FIZZ1 and 
downregulation of M1-associated markers, such as IL-6, TNF and iNOS in 
the polarized macrophages. 
 
 
Illustration 4: Polarization of resting microglia towards the M1 (red) or M2 






1.7.4.3 MiRNAs regulate microglia-mediated neuroinflammation and 
neuropathology 
Recently, several miRNAs have been shown to be  involved in microglial 
activation in various CNS pathologies (see Illustration 5) such as HIV-1 
infection (Mishra et al. 2012; Jadhav et al. 2014), Japanese encephalities virus 
infection (Pareek et al. 2014; Thounaojam et al. 2014), Alzheimer’s disease 
(Guedes et al. 2014), ischemia (Zhao et al. 2013; Kong et al. 2014), prion 
disease (Saba et al. 2012), normal physiological processes such as ageing 
(Fenn et al. 2013) and signalling pathways such as MAPK signalling (Jadhav 
SP et al. 2014), thus modulating neuroinflammation.  
 
 
Illustration 5: MiRNAs involved in microglial activation in various CNS 
pathologies (red) and miRNAs aiding normal physiological process such as 




The ability of miRNAs to regulate diverse cellular processes with 
negligible adverse events qualifies them as extremely potent therapeutic 
agents. Indeed the evidence reviewed above suggests using miRNAs as novel 
“Epidrugs” with a view to reduce microglia-mediated neurotoxicity. For 
example, overexpressing anti-inflammatory miRNAs (such as miR-124) and 
suppressing proinflammatory miRNAs (such as miR-155) could reduce 
microglia activation and subsequently neuroinflammation. This could be 
useful for the treatment of CNS inflammatory diseases such as multiple 
sclerosis (MS). However, altered miRNA expression occurring during 
microglial activation in pathological conditions has not been documented on a 
genome wide scale till date and this should be the focus of future research. 
Thus, disease-specific miRNA profile can be used for diagnosis, prognosis, 
and treatment of various neuroinflammatory conditions and will facilitate the 
development of small RNA molecules in anti-inflammatory therapy with an 
attempt to ameliorate the damage caused by chronic activation of microglia in 
CNS infection, injury and neurodegenerative diseases. 
 
1.8 LPS as tool for microglial activation 
Lipopolysaccharide (LPS) is a constituent of the cell wall of Gram negative 
bacteria (Kulp and Kuehn 2010). LPS is a prominent inducer of microglial 
activation both in vivo and in vitro (Dheen et al. 2007; Cazareth et al. 2014). 
LPS binds to the CD14 protein expressed on microglial cell surface (Kitchens 




with LPS or TNF (Nadeau and Rivest 2000).  CD14 acts as a co-activator 
along with Toll like receptor 4 (TLR4) for the detection of LPS (Zanoni et al. 
2011). TLRs are a class of pattern recognition receptors (PRRs) that recognize 
conserved moieties from pathogens that are different from host molecules and 
are thus important members of the innate immune response (Akira and Takeda 
2004). Binding of LPS to the TLR4 on microglia activates the MAPK and 
NFκB pathways (Lu et al. 2008) leading to production of proinflammatory 
mediators like TNF, and interleukins perpetuating microglial activation (Qin 
et al. 2007).  
 
1.9 Traumatic brain injury model of neuropathology 
Application of an external mechanical force to the brain leads to brain trauma, 
leading to a temporary or permanent impairment in cognitive, behavioral, or 
physical functions (Maas et al. 2008). TBI leads to a broad spectrum of 
neurological defects some of which are irreversible severely influencing the 
quality of life (Saatman et al. 2008). Though the underlying pathophysiology 
of TBI is not well known, it is now appreciated that multiple molecular and 
cellular mechanisms involving inflammation, apoptosis and altered neuronal 
plasticity may play a role. Of particular importance is the microglia-mediated 
inflammation in the hippocampus leading to increased neuronal cell death, 
thus contributing to increased cognitive dysfunction (Hernandez-Ontiveros et 
al. 2013). Several animal models of TBI have been developed with the fluid 
percussion injury model (FPI) being popular due to its reproducibility (Xiong 





1.10 Culture of microglial cells 
 
1.10.1 Culture of primary microglia 
Primary microglia are grown as a mixed culture of cortical glial cells isolated 
from neonatal rodent pups. Usually, primary dissociated mouse brain and rat 
brain cultures after 2 weeks in vitro culture develop a confluent layer of 
fibroblast-like astrocytes above which microglia, are seen distributed 
throughout the culture. Following 10-14 days in culture, microglia are purified 
from the other cells by mild trypsinization. This method selectively removes 
the astrocytic layer and retains the microglia. Highly pure (>95%) microglial 
cells can be obtained by this method with microglial purity being assessed by 
OX-42/Cd11b staining (Hassan et al. 1991). Cultured microglia display 
properties of mononuclear phagocytic cells such as nonspecific esterase 
activity, display of the macrophage surface antigens MAC-l and MAC-3, and 
acetylated low-density lipoprotein receptors. Cultured microglia also display 
functions similar to microglia in vivo such as the ability to engulf 5 pm latex 
beads, to secrete proinflammatory cytokines such as interleukins and TNF in 
response to LPS treatment (Giulian and Baker 1986).  
 
 
1.10.2 BV-2 cell line 
BV-2 cells were developed from raf/myc-immortalised murine neonatal 
microglia and are the most frequently used substitute for primary microglia. It 




in terms of cytokine secretion, MAP kinase signalling and phagocytosis (Hirt 
and Leist 2003). It has also been demonstrated that 90% of the genes induced 
in BV-2 by LPS were also found in primary microglia, and around 50% were 
even found in hippocampal microglia after in vivo stimulation of mice by 
intracerebroventricular injection of LPS (Henn et al. 2009). Furthermore, BV-
2, stimulated by LPS, can also trigger activation in astrocytes as assessed by 
translocation of the transcription factor NF-κB and secretion of the cytokine Il-
6 (Henn et al. 2009). BV-2 cell line was used for miRNA functional analyses 





















2.1 To perform a miRNA microarray of control and LPS-
activated, amyloid -activated primary microglia 
MiRNAs are novel epigenetic factors regulating gene expression by degrading 
their target mRNA or inhibition of protein translation. Altered miRNA 
expression has been observed in microglia in various CNS pathologies. 
However a comprehensive catalogue showing the miRNA expression in 
activated microglia is lacking. The main objectives of this study are as 
follows- 
a. To identify the differentially expressed miRNAs in activated microglia. 
b. To perform pathway analysis to understand miRNAs involved in the 
signaling pathways affecting microglial activation. 
 
2.2 To understand the role of miR-27a in regulating TGF 
signaling pathway in microglia 
MiR-27a was predicted to target SMAD2, TβR1 and Runx1, members of the 
TGFβ signalling pathway in microglia. TGFβ1 is an anti-inflammatory 
cytokine and TGFβ signalling via SMAD2/3 has been shown to lead to 
microglial quiescence. Thus it is hypothesized that miR-27a promotes the 
proinflammatory response of microglia by suppressing TGFβ-SMAD 
signalling in microglia. 




a. To check the expression of miR-27a in LPS and TGF activated 
microglia in vitro 
b. To verify if SMAD2, TβR1 and Runx1 are the targets of miR-27a 
by knockdown and overexpression of miR-27a in BV2 microglia 
c. To perform functional studies such as expression of 
proinflammatory cytokines after knockdown and overexpression of 
miR-27a in BV2 microglia 
d. To check neuronal apoptosis mediated by microglia conditioned 
medium after knockdown and overexpression of miR-27a in BV2 
microglia 
 
2.3 To understand the role of miR-200b in regulating 
cJun/MAPK signaling pathway in microglia 
MiR-200b was predicted to target cJun, a member of the mitogen activated 
protein kinase (MAPK) signalling pathway. MAPK pathways regulate 
production of proinflammatory cytokines and cytotoxic molecules by activated 
microglia. Thus it is hypothesized that miR-200b inhibits microglia activation 
by suppressing the cJun/MAPK pathway in microglia. 
The main objectives of this study are as follows- 
a. To check the expression of miR-200b in LPS activated microglia in 
vitro 
b. To verify if cJun is the target of miR-200b by knockdown and 




c. To perform functional studies such as expression of 
proinflammatory cytokines after knockdown and overexpression of 
miR-200b in BV2 microglia 
d. To check neuronal apoptosis mediated by microglia conditioned 























In this study, wistar rats of different ages were used as tabulated below (Table 
1). The animals were procurred from Laboratory Animals Centre, National 
University of Singapore (NUS). This study was approved by the National 
University of Singapore Institutional Animal Care & Use Committee (IACUC) 
and DSO National Laboratories Institutional Animal Care & Use Committee 
(protocol number 059\11 and 080/10). All efforts were made to minimize pain 
and the number of animals used. The rats used in this study are tabulated 
below. 
Table 1: Animals used for the study. 
Experiment Age Number 
Primary culture of 
microglia 
3-day 120 
LPS treatment 5-day 6 
Laser-capture 
microdissection 
2 month 6 
Total  132 
 
 
3.2 Collection of fresh brain samples 
To collect brain samples, 2-month old wistar rats were anaesthetized by 
intraperitonial injection of pentobarbitone (50mg/kg body wt). An incision 




removed carefully followed by washing twice in sterile ice-cold PBS. 
Following washing, the tissue was rapidly frozen in liquid nitrogen in optimal 
cutting temperature compound (OCT)-containing moulds. The tissue was 
stored at -80ºC freezer to inhibit denaturation of samples until further use.  
 
3.3 Treatment of animals with drug 
3.3.1 Materials 
 Lipopolysaccharide (LPS) (Cat No. L6529; Sigma-Aldrich‚ St. Louis, 
MO, USA) 
3.3.2 Procedure 
To inject animals with LPS, it was first diluted in saline (250μl of saline per 
injection). 5-day old rat pups were injected with two doses of LPS 
intraperitoneally (i.p.) (1mg/kg body weight) with an interval of 6h. To serve 
as control, the rat pups were injected with saline (250μl per injection) instead 
of LPS.   
 
3.4 Perfusion   
3.4.1 Principle 
Perfusion is defined as a technique of pouring a liquid on or through an organ. 
Animal perfusion involves injecting a fixative such as formaldehyde or 
alcohol through the body to preserve the structure of the organs and tissue. A 
fixative cross-links the proteins thereby protecting them from degradation 
(Oliver and Jamur 2010). Transcardiac perfusion involves injecting the 




of the fixative to all parts of the body including the brain, through the action of 
the heart (Paul et al. 2008). 
3.4.2 Materials  
 NaH2PO4 (sodium di-hydrogen phosphate) (Cat no S8282, Sigma-
Aldrich‚ St. Louis, MO, USA) 
 Na2HPO4 (di-sodium hydrogen phosphate) (Cat no 255793, Sigma-
Aldrich‚ MO, USA) 
 Paraformaldehyde (PF) (Cat. No. P001, TAAB Laboratories, UK)   
3.4.3 Preparation of Fixative 
Before preparation of the fixative, the buffers sodium di-hydrogen phosphate 
and di-sodium hydrogen phosphate were prepared. To prepare 1000 ml of 
0.1M di-sodium hydrogen phosphate buffer, 14.1g of Na2HPO4 powder was 
dissolved in 1000 ml of distilled water (DW). To prepare 0.1M of sodium di-
hydrogen phosphate buffer, 11.9g of NaH2PO4 powder was dissolved in 
1000ml of DW. Further, to prepare 1 liter of phosphate buffer, 800 ml of the 
above prepared Na2HPO4 solution was mixed with 200 ml of NaH2PO4 
solution. 40g paraformaldehyde powder was dissolved in 1 liter of phosphate 
buffer prepared as described above, by heating, until the PF had completely 
dissolved, to prepare the 4% fixative solution. The fixative was filtered using 
Whatmann paper and chilled prior to use.  
3.4.4 Procedure 
For perfusion the animal was anaesthetized with pentobarbitone (i.p., 30mg/kg 
body wt) followed by the toe pinch test to ensure unresponsiveness. With its 




through the thoracic and abdominal wall along the midline and the diaphragm 
using a scalpel. A needle was put in the left ventricle of the heart and the right 
auricle was clipped with the help of forceps. Ringer’s solution was used to 
flush out the blood. Fixative substituted Ringer’s solution after the liver turned 
pale. The brain tissue was isolated and incubated in PF for 2-3h at 4ºC. Once 
post-fixation was over the tissue was transferred to 15% sucrose solution 
overnight at 4ºC for cryoprotection. 
 
3.5 Traumatic brain injury (TBI) rat model 
Fluid percussion model was used to induce brain trauma in rodents (Dixon et 
al. 1987). Anesthesia was applied to male wistar rats (ketamine (75mg/kg) and 
xylazine (10mg/kg)). Craniotomy was performed midway between bregma 
and lambda by preserving dural layers and a fluid pressure pulse was applied 
to produce brief displacement of neural tissue. Sham operated rats received 
only anaesthetic agent following a midline incision. After injury or sham 
operation, the scalp was sutured, and the animal was allowed to recover from 
anaesthesia and returned to their home cages. 24h after surgery, fresh brain 
tissue was collected and stored at -80ᵒC for LCM analysis.  
 
3.6 Preparation of gelatinized slides 
3.6.1 Materials 
 Gelatin (Cat no 1.04080, Merck Millipore, Germany) 
 Chrome alum (Chromium (III) potassium sulfate (Cat no 1.01036, 






To prepare gelatin solution, 9g of gelatin was dissolved in 600 ml distilled 
water by constant stirring with heat until gelatin had completed dissolved. The 
slides were washed with alcohol and air dried. Once the gelatin solution had 
cooled, 0.9g chrome alum was mixed in the gelatin solution and filtered using 
Whatman’s filter paper. The washed slides were gelatin coated by immersing 
in the gelatin solution for 1 min followed by air drying and storage at 37°C.   
 
3.7 Cryosectioning of brain tissue 
3.7.1 Materials and equipment 
 Cryostat (Leica CM 3050 S, Leica-Microsystems, Nussloch, GmbH, 
Germany) 
3.7.2 Procedure 
For cryosectioning of brain tissue, the brain sample was attached onto a metal 
chuck by application of optimal cutting temperature compound followed by 
quick freezing in liquid nitrogen. Following this the sample was left in the 
cryostat for a period of 10-15 min until the entire tissue froze completely. The 
brain tissue was then cut at 30 µm thickness for immunohistochemistry and 
arranged on gelatin slides. The corpus callosum was chosen for further 
experiments. For LCM, the brain samples were cut at 10 µm thickness and 
placed on MMI metal slides. The hippocampus was selected for LCM 








3.8.1 Principle of immunohistochemistry 
Immunohistochemistry defined as detecting a protein of interest on a particular 
tissue. For this purpose, a primary antibody raised against the protein of 
interest is used followed by using a secondary antibody raised against the 
primary antibody. The secondary antibody is usually tagged with an enzyme 
such as horseradish peroxidase or with a fluorophore such as cy3 or FITC 
allowing visualization either by color development or under a confocal 
microscope (Fritschy Jean-marc 2001; Matos et al. 2010). 
 
3.8.2 Materials 
 Phosphate buffered saline (PBS; BUF-2041-1x1L, 1st Base, Singapore)  
 Peroxidase conjugated isolectin (Cat # L5391, Sigma-Aldrich, MO, 
USA)   
 Water, Diethylpyrocarbonate (DEPC) treated, Biotechnology Grade, 
1L  (BUF-1170-1L, 1
st
 Base, Singapore) 
 30% Hydrogen peroxide (H2O2) solution 
 DAB solution 
3.8.3 Procedure for staining microglia on fresh brain sections 
IHC on fresh frozen tissue for LCM analysis was carried out rapidly to 




ethanol for 1 min followed by incubation with peroxidase conjugated isolectin 
for 15 min at room temperature. This was followed by dehydration using a 
graded series of ethanol. For color development, the sections were incubated 
in DAB solution in the dark. Lectin-marked microglia were stained in brown.  
 
3.8.4 Materials 
 Rabbit-anti-SMAD2 antibody (Cat # D43B4, Cell Signaling Tech, 
USA) 
 Rabbit anti-TGFβ1 antibody (Cat # sc 28679, Santa Cruz Biotechn., 
Texas, USA) 
 Rabbit anti-TβR1 antibody (Cat # sc 398, Santa Cruz Biotechn., Texas, 
USA) 
 Mouse anti-Integrin-αM/Cd11b antibody (Cat # CBL1512, Merck 
Millipore, Billerica, MA, USA) 
 goat anti-rabbit IgG Cy3 (Prod # AP132B, Merck Millipore, Billerica, 
MA, USA) 
 Goat anti-mouse IgG FITC (Prod # AP132F, Merck Millipore, 
Billerica, MA, USA) 
 DAPI (Cat # D3571, Molecular Probes, Invitrogen, Life Technologies, 
Thermo Fisher Scientific Inc, MA, USA) 
 Phosphate buffered saline (PBS; BUF-2041-1x1L, 1st Base, Singapore) 
 Mounting Medium (Cat # S302380, Dako, Agilent Technologies, 
USA) 




 Olympus FV100 confocal laser-scanning microscope (FV-1000, 
Olympus Optical Co., Japan) 
3.8.5 Procedure for immunofluorescence on fixed brain tissues 
For tissue staining, the fixed frozen tissue sections given a quick wash in 
1XPBS followed by blocking in 10% goat serum for 1h at room temperature. 
Care was taken to ensure that the sections do not dry out during the entire 
procedure. Following blocking, the sections were incubated with a primary 
antibody mixture of anti-Cd11b and either anti-SMAD2 or anti-TGFβ1 or anti-
TβR1 antibodies, overnight at 4ºC. The next day, tissue sections were washed 
in 1XPBS. This was followed by incubation with a mixture of anti-mouse 
FITC and anti-rabbit Cy3 secondary antibodies for 1h at room temperature. 
Following secondary antibody incubation, nuclei were stained using DAPI. 
Nuclear staining was followed by a further 3 washes with 1XPBS. Finally, the 
sections were mounted in DAKO fluorescent mounting medium. Images were 
captured using an Olympus confocal microscope. 
 
3.9 Laser-capture microdissection of microglia from adult rat 
brain tissue 
3.9.1 Principle of LCM 
Laser capture microdissection enables isolation of specific cells from a mixed 
population, under microscopic visualization. These samples can be further 
used for various biological analysis including downstream next-generation 
sequencing, Sanger sequencing, PCR, and proteomics. LCM is an important 




heterogeneous cell population, thereby allowing us to understand the effect of 
the tissue microenvironment on the cell under consideration.  
3.9.2 Materials 
 MMI Transparent caps (Cat # 50208, Molecular Machines & 
Industries, Switzerland) 
 MMI CellCut (Molecular Machines & Industries, Glattbrugg, 
Switzerland) 
3.9.3 Procedure 
Laser-capture microdissection of microglia was carried out by arranging the 
metal slides with lectin stained microglial sections on the stage of the laser-
capture microdissection microscope. The isolation caps were arranged above 
the hippocampus and cells were identified and cut using the laser. A minimum 
of 800 cells were isolated per sample.  
 
3.10 Extraction of RNA from laser-captured microglia 
3.10.1 Principle of RNA extraction 
Two important aspects of RNA isolation are maintenance of RNA integrity 
during the extraction process and a complete removal of contaminating protein 
and DNA. Single step RNA isolation procedure using guanidine thiocyanate 
combined with phenol gives the best results including increased RNA yield 
from the tissue/cell preparation (Chomczynski and Sacchi 2006). Recently, the 
miRNeasy kit developed by Qiagen combines the above-mentioned procedure 
along with a downstream silica-membrane based purification process to yield 





 QIAzol Lysis Reagent (Qiagen, Prod # 79306, Germany) 
 miRNeasy mini kit (Qiagen, Prod # 74106, Germany) 
 Nanodrop (Thermo Scientific, Model No. ND1000, MA, USA)  
3.10.3 Procedure 
The QIAzol reagent, which is a combination of phenol and guanidine-
thiocyanate was used for lysing the laser-captured microglial cells. The lysate 
was mixed with chloroform and separated into upper aqueous, interphase and 
lower organic phases. The upper aqueous phase containing RNA was carefully 
pipetted out. This was put together with 70% ethanol and added to the 
miRNeasy column to “capture” the RNA on the membrane in the column.  
The flow through was discarded. After washing the column with wash buffer 
provided in the kit, total RNA along with small and miRNAs was eluted in 
15µl of warm nuclease-free water. The RNA quality and concentration were 
measured using a nanodrop. An aliquot of RNA was prepared for cDNA 
conversion while the rest was immediately stored at -80°C.   
 
3.11 Synthesis of cDNA from LCM-extracted RNA 
3.11.1 Principle 
Complementary DNA (cDNA) is reverse transcribed from RNA using an 
enzyme known as reverse transcriptase. Reverse transcriptase is a RNA-
dependent DNA polymerase, which uses mRNA as a template, to produce its 





 SuperScript® VILO™ cDNA Synthesis Kit (Cat #11754050, 
Invitrogen, Life Technologies, Carlsbad, CA, USA) 
 Mastercycler gradient thermal cycler (Cat # 950000015, Hamburg, 
Germany) 
3.11.3 Procedure 
Since the amount of RNA obtained using LCM is very low, cDNA conversion 
was achieved using a thermostable reverse transcriptase enzyme which 
improves cDNA yield, and qRTPCR results.  About 300ng of total RNA was 
mixed with 4 l of 5X reaction mix containing random primers, MgCl2, and 
dNTPs, 2 l of 10X SuperScript® VILO™ enzyme. Appropriate volume of 
DEPC water was used to bring up the reaction volume to 20 l. This mixture 
was incubated according to the following protocol in a Mastercycler gradient 
thermal cycler: 42°C   for 60 min and 85°C for 5min. The resulting cDNA was 
stored at -20C until further use. 
 
3.12 Cell Culture 
3.12.1 Primary culture of microglia 
3.12.1.1 Materials 
 DMEM (Prod # 11965-092, Gibco, USA) 
 Fetal bovine serum (Prod # 10100-147, Gibco, USA) 





 Phosphate buffered saline (PBS; BUF-2041-1x1L, 1st Base, 
Singapore) 
 Trypsin-EDTA solution (Sigma-Aldrich, Prod # T4049, USA) 
 70µm cell strainer (BD Biosciences, Prod # 352350, USA) 
 0.5M EDTA (Sigma-Aldrich, Prod # E-7889, USA) 
 Insulin (Bovine) (Sigma-Aldrich, Prod # I0305000, USA) 
 Antibiotic antimycotic solution 100X (Sigma-Aldrich, Prod # 
A5955, USA)  
3.12.1.2 Procedure 
Complete medium for primary microglia culture was prepared using 450 ml 
DMEM, 5 ml of antibiotics, 50 ml of FBS, 5 ml of non-essential amino acids, 
and 625 µl of insulin. Brain cortices from 3-day-old rat pups were removed 
and cleaned in ice-cold sterile PBS followed by removal of the meninges. The 
tissues were mechanically minced followed by enzymatic digestion with TE 
and DNase at 250rpm for 15min in a humidified atmosphere of 37ºC. Further, 
the cell suspension was filtered through a 70 µm cell strainer followed by 
seeding in complete medium. The cells were cultured at 37°C in an incubator 
with 5% CO2 and 95% air incubator. Mixed glial cells were cultured for 10-12 
days and the medium was changed every other day. Microglia purification 
from the mixed glial culture was carried out using the trypsination method. 
Briefly, the cultures were given a warm 1X PBS wash. The trypsin solution 
was prepared by mixing 1 ml of 10X trypsin with 20 µl of 0.5mM EDTA in 39 
ml of DMEM without serum. The cells were incubated with the trypsin 




from the flask and discarded. Microglial cells remaining in the flask were 
washed with PBS. The cells were allowed to rest in complete medium for 24h 
followed by further analyses.   
3.12.2 BV-2 cell culture 
3.12.2.1 Materials 
 Dulbecco’s Modified Eagle’s Medium (Cat # 11965-092, Gibco, 
Life Technologies, CA, USA) 
 Fetal bovine serum (Cat # 10100-147, Gibco, Life Technologies, 
CA, USA) 
 Phosphate buffered saline (PBS; BUF-2041-1x1L, 1st Base, 
Singapore) 
 Trypsin/EDTA solution (Cat # R001100, Life Technologies, CA, 
USA) 
3.12.2.2 Procedure 
A widely used murine microglial cell line, BV-2 microglial cells were 
maintained in complete medium consisting of, DMEM and 10% FBS, and 
cultured in an incubator at 37°C with 5% CO2 and 95% air. For subculturing, 
the cells were washed with PBS followed by treatment with 1X trypsin-EDTA 
solution in PBS for 5min at 37°C. The enzymatic reaction was neutralized by 
complete medium and cells were collected by centrifugation at 1000 rpm for 
5min at 4°C. The pellet was re-suspended in fresh complete medium. Cells 
were seeded on 96 well plates at a density of 1.0 × 103 for cell viability assay, 
and on 6-well plates at a density of 2.0 × 105 per well for protein and RNA 




2.0 × 104 cells were used per well in six well plates or 24 well plates, 
respectively. BV-2 cells were treated with LPS at 1 μg/ml for 1 to 6h to 
activate microglia. 
 
3.12.3 Neuronal Cell Culture  
 
3.12.3.1 Materials 
 Dulbecco’s Modified Eagle’s Medium (Cat # 11965-092, Gibco, 
Life Technologies, CA, USA) 
 Fetal bovine serum (Cat # 10100-147, Gibco, Life Technologies, 
CA, USA) 
 Phosphate buffered saline (PBS; BUF-2041-1x1L, 1st Base, 
Singapore) 
 Trypsin/EDTA solution (Cat # R001100, Life Technologies, CA, 
USA) 
 Sodium butyrate (Cat # B5887, Sigma Aldrich, MO, USA)  
3.12.3.2 Procedure 
MN9D dopaminergic neuronal cell line was grown in DMEM and 10% FBS, 
cultured at 37°C with 5% CO2. The cells were differentiated into dopaminergic 





3.13 MiRNA profiling 
3.13.1 Principle 
MiRNA microarray is a high-throughput method for screening genome-wide 
miRNA expression profile across samples. Using this method, large sample 
collection can be processed in parallel. MiRNA oligo probes designed on the 
sense strand of the miRNA for the detection of either mature miRNA or 
precursor miRNA are used as “capture” probes. Either biotinylated or 
fluorescently labelled RNA samples are hybridized to the capture probes 
followed by detection of the signal by a laser. The Exiqon miRCURY LNA™ 
microRNA Array slides contain capture probes complementary to mature 
microRNAs registered in miRBase.  
 
3.13.2 Procedure 
Prior to miRNA microarray analysis, quality of RNA samples was assessed 
using an Agilent 2100 Bioanalyzer profile. The bioanalyzer provides a RIN 
value (RNA Integrity Number ranging from 0 to 10), which gives a reliable 
impression of the quality of the RNA (Schroeder et al. 2006). RIN value for 
all samples was above 7, which is indicative of good quality, unfragmented 
RNA. Total RNA (400ng) from control and activated microglia samples was 
labeled with Hy3™ and Hy5™ fluorescent label, respectively, using the 
miRCURY LNA™ microRNA Hi-Power Labeling Kit (Exiqon, Denmark) 
following manufacturer’s instructions. The Hy3™-labeled and Hy5™- labeled 
reference RNA samples were mixed pair-wise and hybridized to the 




microarray chip contains capture probes targeting all microRNAs for human, 
mouse or rat registered in the miRBASE 18.0. A Tecan HS 4800™ 
hybridization station (Tecan, Austria) was used to perform the hybridization 
reaction. The microarray slides were scanned using the Agilent G2565BA 
Microarray Scanner System (Agilent Technologies, Inc., USA). Analysis of 
the data obtained was carried out using the ImaGene 9.0 software 
(BioDiscovery, Inc., USA). The quantified signals were background corrected 
(Ritchie et al. 2007) and normalized using the global Lowess (LOcally 
WEighted Scatterplot Smoothing) regression algorithm. The microRNA 
microarray experiment was conducted at Exiqon, Denmark.  
 
3.14 MiRNA pathway analysis 
MiRNA pathway analysis was carried out using the Ingenuity pathway 
analysis (IPA) software. MiRNAs identified from the microarray analysis as 
having the highest fold change across samples were fed into the software 
which identified the mRNAs targeted by these miRNAs. Highly predicted and 
experimentally verified targets as per the Targetscan database were considered 
for further analyses.  
 
3.15 MiRNA functional analysis 
3.15.1 miRNA knock down  
3.15.1.1 Principle 
miRNA inhibitors or anti-miRs are chemically modified antisense 




inhibition of the miRNA and increased expression of the direct target genes 
(Stenvang et al. 2012). Beacuase of the small size of these chemical inhibitors, 
anti-miRNAs can be easily transfected in mammalian cells where they bind to 
the endogenous miRNA. This leads to a reduction of the levels of the specific 
miRNA under consideration. The functional activity of a miR inhibitor can be 
checked by assessing the mRNA expression of its target gene by qRT-PCR or 
protein expression by western blot. However, predominantly the mRNA 
expression of a target gene may not be affected since miRNAs regulate gene 
expression post-transcriptionally (Valastyan and Weinberg 2009). 
 
3.15.1.2 Materials 
 miRCURY LNA™ microRNA inhibitor (Exiqon, Vedbaek, Denmark) 
 OptiMEM medium (Cat # 31905070, Invitrogen, Life technologies) 
 X-tremeGENE siRNA transfection reagent (Cat. No. 04476093001, 
Roche Applied Sciences) 
3.15.1.3 Procedure 
For functional analysis of miRNAs in microglia, BV2 cells were seeded in 6 
well plates at a density of 2 × 105. Transfection was carried out using X-
tremeGENE siRNA transfection reagent. 5’fluorescent labelled miRCURY 
LNA
TM
 microRNA inhibitors and control scrambled miRNA were purchased 
from Exiqon. Table 2 summarizes the sequences of the inhibitors.  MiRNA 
inhibitors were diluted in opti-MEM medium and added to the cells at final 
concentration of 40nM of the inhibitors. Western blot analysis was used to 




Table 2: Sequence of miRNA inhibitors purchased from Exiqon (Vedbaek, 
Denmark)  














4101960-001 Mmu-miR-27a CGGAACTTAGCCACTGTGA Unlabelled 
 
3.15.2 miRNA overexpression 
3.15.2.1 Principle 
MiRNA mimics are small, chemically modified double-stranded RNAs. These 
molecules mimic endogenous miRNAs, leading to up-regulation of miRNA 
activity. Use of chemical miRNA mimics is advantageous as it enables 
targeting of a specific mRNA and provides a possibility of in vivo delivery 
using lipid- or polymer-based nanoparticles (Wang 2011). 
 
3.15.2.2 Materials 
 mirVANATM miRNA mimic (Ambion, Life Technologies) 
 X-tremeGENE siRNA transfection reagent (Cat. No. 04476093001, 
Roche Applied Sciences) 






For overexpression of miRNAs in microglia, BV2 cells were seeded in 6 well 
plates at a density of 2 × 105. Transfection was carried out using X-
tremeGENE siRNA transfection reagent. Non-labelled mirVANA
TM
 miRNA 
mimic and scrambled negative control were purchased from Ambion (Life 
Technologies). Table 3 summarizes the sequences of miRNA mimics.  
MiRNA mimics were diluted in opti-MEM medium at final concentration of 
20 nM. Western blot analysis was used to evaluate the protein expression of 
the target mRNA 48h after transfection.  

























3.16 Cell Viability Assay 
3.16.1 Principle 
Cell viability was measured using a calorimetric assay known as MTS assay. 
NADPH generated by dehydrogenases in viable cells converts tetrazolium 
compound (Owen’s reagent, [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt;) to a 
colored formazan product and thus is a direct measure of cell viability. The 
quantity of formazan is measured colorimetrically by absorbance at 490nm. 
3.16.2 Materials 
 CellTiter 96R AQueous Non-Radioactive Cell Proliferation Assay (Prod 
# G5421, Promega, WI, USA) 
3.16.3 Procedure 
Cell viability post transfection was measured using the colorimetric MTS 
assay, which is non-radioactive cell proliferation assay, as per manufacturer’s 
instructions. Briefly 5000 BV2 cells were seeded in 96 well plates and 
transfected as mentioned above. 24h post transfection, 20µl of MTS/PMS 
solution was added to each well. Next, the plate was incubated in 37°C in a 
humidified atmosphere of 5% CO2 and 95% air incubator for 3h and the 
absorbance was measured using a microplate spectrophotometer at 490 nm. 





3.17 Luciferase Assay 
3.17.1 Principle 
The luciferase reporter assay is a tool to assess transcriptional activity. 
Luciferases are oxidative enzymes found in several species such as fireflies 
allowing the organisms to emit light (Gould and Subramani 1988). For the 
reporter assay, the regulatory region of gene-of-interest is cloned upstream of 
the luciferase gene in an expression vector. This is known as a reporter 
plasmid. This plasmid is transfected into cells.  The luciferase enzyme activity 
can be measured using a spectrophotometer after addition of the substrate 
luciferin. Since the gene of interest is fused to the luciferase reporter gene, the 
luciferase activity can be directly correlated with the activity of this gene. 
3.17.2 Materials 
 pMiRTarget luciferase reporter containing the 3’UTR of cJun (custom 
made, OriGene Technologies, Rockville, MD, USA) 
 ONE-GloTM Luciferase assay (Cat # E6110, Promega, Madison, WI, 
USA)  
3.17.3 Procedure 
pMiRTarget luciferase reporter vector containing the 3’UTR of cJun cloned 
into the multiple cloning site was purchased from OriGene Technologies 
(custom made). BV2 cells were cotransfected with 80ng of the luciferase 
reporter plasmid along with miRNA mimics (final concentration 20 nM). 48h 
post transfection, luciferase activity was evaluated using the ONE-Glo
TM
 
Luciferase assay system. pMiRTarget luciferase reporter vector also encodes 




monitoring and normalization. Each experiment was repeated twice in 
triplicate. 
 
3.18 In situ hybridization 
3.18.1 Principle 
In situ hybridization is a technique to obtain temporal and spatial 
expression pattern of gene of interest by localizing specific nucleic acid 
targets within fixed tissues and cells (Jin and Lloyd 1997). A labeled 
complementary DNA or RNA strand (i.e., probe) is used to localize a 
specific DNA or RNA sequence in a tissue (in situ), or cells. This technique 
is very useful in revealing the location of specific nucleic acids sequences 
on chromosomes or in tissues which is a important for understanding the 
organization, regulation and function of genes. This technique is further 
extended to study the localization of miRNAs in tissue or cells.  
3.18.2 Materials 
 miRCURY LNA™ microRNA ISH Buffer Set (Prod No. 90000, 
Exiqon) 
 miRCURY LNA TM probe mmu-miR-200b (Prod No. 88080-04, 
Exiqon) 
 miRCURY LNA TM probe U6 (Prod No. 99002-04, Exiqon) 
 DAPI (Cat # D1306, Molecular probes, Invitrogen, Life Technologies) 







In situ hybridisation was carried out to localze miR-200b in microglia using 
Exiqon’s miRCURY LNA™ microRNA ISH Buffer Set. BV2 cells were 
seeded at a cell density of 2 × 10
4
 on poly lysine coated cover slips 
overnight.  The cells were fixed with freshly prepared 4% PF and 
permeabilized using the ISH buffer provided in the kit. 5’ fluorescein 
labelled miRCURY LNA 
TM
 probe mmu-miR-200b (Prod No. 88080-04, 
Exiqon) was used to localise the mature miR-200b while 5’ fluorescein 
labelled miRCURY LNA
 TM
 probe mouse U6 (Prod No. 99002-04, Exiqon) 
served as a positive control. Further, the nucleus was stained with DAPI 
(1µg/ml) and coverslips were mounted on glass slides with fluorescent 
mounting medium. Images were captured using an Olympus confocal 
FV1000 microscope. The sequences for the probes used are listed in table 
4. 






























3.19 RNA isolation and quantitative real-time RT-PCR 
(qRTPCR) 
3.19.1 Isolation of total and small RNA 
3.19.2 Material 
 QIAzol Lysis Reagent (Prod# 79306, Qiagen, Germany) 
 miRNeasy mini kit (Prod# 74106, Qiagen, Germany) 
 70% ethanol 
 β-mercaptoethanol (Prod# M6250, Sigma Aldrich, MO, USA) 
3.19.3 Procedure  
For RNA isolation from LPS treated primary and BV2 cells, 700 µl Qiazol 
reagent was added to each sample. After vigorous mixing, the lysate was 
mixed with chloroform and separated into upper aqueous, interphase and 
lower organic phases. The upper aqueous phase containing RNA was 
pipetted out. This was put together with 70% ethanol and added to the 
miRNeasy column to “capture” the RNA on the membrane in the column. 
The flow through was discarded. After washing the column twice with 
wash buffer provided in the kit, total RNA along with small and miRNAs 
was eluted in 15 µl of nuclease-free water. The RNA quality and 
concentration were measured using a sphectrophotometer. An aliquot of 
RNA was prepared for cDNA conversion while the rest was immediately 




3.20 Reverse transcription of RNA into cDNA 
3.20.1 Material 
 dNTP mix (Cat # U1511, Promega, Madison, USA) 
 Moloney murine leukemia virus reverse transcriptase (Prod # M1705, 
Promega, Madison, USA) 
 Moloney murine leukemia virus reverse transcriptase buffer pack (Prod 
# M5313, Promega, Madison, USA) 
 RNase inhibitor (Cat # AM2694, Invitrogen, USA) 
 Oligo (dT) (Cat # AM5730G, Invitrogen, USA) 
3.20.2 Procedure  
For the first step of cDNA conversion, 2μg RNA from each sample was 
mixed with 2 μl of oligodT primer and incubated at 70ºC for 5min. A 
master mix of 5 μl M-MLV buffer, 1μl M-MLV enzyme, 1.5 μl dNTP mix 
and 0.7 μl of Rnase inhibitor were prepared for each sample. After cooling 
the RNA oligodT mix on ice for 5min, the above master mix was added to 
the samples. The cDNA mixture was incubated according to the following 
protocol in a Mastercycler gradient thermal cycler: 42°C    for 60’ and 95°C 
for 5 min.  The resulting cDNA was stored at -20C until further use. 
3.21 Quantitative real time RT-PCR  
3.21.1 Principle 
Real time polymerase chain reaction (RTPCR) is a biochemical process used 
to amplify a specific region of DNA or gene of interest from a small amount of 




o Melting or denaturation of DNA to yield a single strand of 
DNA from the duplex 
o Annealing of primers to the single stranded region of interest 
o Elongation of the DNA strand by addition of dNTPS, Taq 
polymerase enzyme and forward and reverse oligonucleotides 
(primers) specific to that region.  
RTPCR has the advantage of allowing the quantitation of the DNA formed 
after each cycle by the use of double-stranded DNA intercalating dyes such as 
SYBR green or fluorescent probes (TaqMan chemistry). The SYBR green 
method measures the amount of intercalated dye in the double stranded DNA 
and provides a number known as the cycle threshold (Bustin 2000). The 2
-
[ΔΔCt]
 method is used to calculate the fold change in gene expression of gene of 
interest when compared to control (Livak and Schmittgen 2001). 
3.21.2 Material and instrument 
 Fast SYBR® green master mix (Prod # 4385617, ThermoFisher 
Scientific, Applied Biosystems, USA) 
 7900HT Fast real-time PCR system (Thermo Fisher Scientific, Applied 
Biosystems, USA) 
 MicroAmp® Optical 96-Well Reaction Plate (Prod # 4306737, Life 
Technologies, USA) 
3.21.3 Procedure 
The qRTPCR reaction mixture (10µl) included the following reagents: 
o Fast SYBR green master mix (containing ROX dye and dNTPs)      5µl   




o Reverse primer (0.5µM)                                                                  0.5 µl    
The cDNA used for qRTPCR was diluted 1:10 with nuclease-free water to a 
final volume of 10µl. Table 5 summarizes the primer sequences of the genes 
under consideration. The PCR reaction was as follows: 
95°C      1s 
60°C     20s 
PCR products were subjected to agarose gel electrophoresis to ensure primer 
specificity by detection of the presence of a single band. 
Table 5: Sequence of primers used for qRT-PCR analysis (mouse) 
















5'- GCC CAT CCT CTG TGA 
CTCAT-3' 















































5’-GTG ATG CGT ATC CCC 
GTA GA-3’ 










Table 6: Sequence of primers used for qRT-PCR and semi-quantitative PCR 
analysis (rat) 
























































5’- AAC CCT CAG CCT CAA 
AGT CA-3’ 











3.22 Agarose gel electrophoresis 
3.22.1 Principle  
This is a quick and cost effective way to separate DNA based on its size. As 
DNA carries a negative charge, it migrates through the agarose matrix towards 
the positive electrode after application of an electric current to the 
electrophoresis tank. The migration of DNA through the matrix depends on its 
size, with higher molecular weight fragments running slower while smaller 
molecular weight frangments running faster towards the positive electrode. 
Intercalating dyes such as SYBR green or ethidium bromide (EtBr) are added 
to the agarose gel to enable visualization of the DNA bands (Waring 1965). 
3.22.2 Materials and Instrument 
 Blue/Orange loading dye 6X (PRG1881, Promega Corporation, 




 Certified Molecular biology agarose (Cat. No. 161-3102, Bio-Rad, 
MO, USA) 
 Tris acetate EDTA buffer (BUF-3001-10X1L, 1st Base, Singapore) 
 DNA ladder 100bp (Cat # G2101, Promega, Madison, USA) 
 Ethidium bromide (EtBr) (Invitrogen, Life Technologies, USA) 
 Image Lab TM (Bio-Rad CA, USA) 
3.22.3 Procedure 
To prepare a 2% gel, 2g agarose was dissolved in 100ml TAE buffer in a 
microwave oven. After cooling, 6 μl of EtBr was mixed in the agarose solution 
and poured onto a gel-tray. 10 μl PCR products were mixed with 2μl of 
loading dye and loaded onto wells in the agarose gel. 5μl of 100 bp DNA 
ladder was loading in one well to determine the sie of the product. After 
running the gel until the dye front reached the end of the gel, the DNA was 




3.23 Immunocytochemistry  
3.23.1 Principle 
Immunocytochemistry localizes a specific protein of interest in cells. A 
fluorophore tagged secondary antibody is used to tag the primary antibody and 
the resulting fluorescent signal is captured using a microscope. 
3.23.2 Material 
 4% paraformaldehyde (PF) 
 Lectin from Lycopersicon esculentum FITC conjugate (Cat # L0401, 




 Goat anti-rabbit IgG- cy3 antibody (Cat # AP132B, Merck Millipore, 
Billerica, MA, USA) 
 goat anti-mouse IgG-FITC antibody (Cat # AP132F, Merck Millipore, 
Billerica, MA, USA) 
 DAPI (Cat # D3571, Molecular Probes, Invitrogen, Life Technologies, 
Thermo Fisher Scientific Inc, MA, USA) 
 Mounting Medium (Cat # S302380, Dako, Agilent Technologies, 
USA) 
 Goat serum (Cat # S-1000, Vector Laboratories, Burlingame, USA) 
Table 7: Antibodies used for immunostaining. 




































Rabbit sc 649 
Cd11b Merck Millipore Mouse CBL1512 
 
3.23.3 Procedure 
For performing immunocytochemistry, the first step was to coat glass 
coverslips placed in each well of a 24-well plate, with poly-l-lysine for 2h at 
room temperature. 2 × 10
4
 BV2 microglial cells were seeded in each well and 
allowed to grow for 24h in a 37°C incubator. The following day, the cells were 
fixed with chilled, freshly-prepared 4% PF for 20 min at room temperature. 
Following fixation, blocking was performed with 5% goat serum for 30 min at 
room temperature. The cells were incubated with primary antibody overnight 
at 4
0
C. The next day, after washing, the cells incubated with secondary 
antibodies for 1h at room temperature. Further, following 3 PBS washes, the 
nucleus was stained with DAPI. Coverslips were mounted onto glass slides 
cleaned with 70% alcohol. After air-drying, images were captured with laser 





3.24 Nitrite Quantification 
3.24.1 Principle 
Nitric oxide (NO) is a secretory product of mammalian cells playing a role in 
immune response (Moncada and Higgs 1993). NO production and secretion is 
elevated during an immune response. In biological systems, NO is oxidized to 
nitrite and nitrate which are used to quantitate NO production (Snyder and 
Bredt 1992). The Griess reaction involves the conversion of nitrate to nitrite 
by the enzyme nitrate reductase. This results in the formation of a coloured 
dye whose absorbance can be measured at 540 nm (Kelm et al. 1997). 
3.24.2 Materials 
 Cell culture medium 
 Nitric Oxide Colorimetric BioAssay TM kit (US Biologicals, MA, 
USA) 
3.24.3 Procedure 
Measurement of nitrite in culture supernatant provides a means to measure the 
NO production in cell culture systems. Culture supernatant was collected from 
BV2 cells transfected with control and miRNA inhibitors and mimics.  85µl 
culture supernatant was added to each well of a 96-well ELISA plate and 
mixed with 5µl each of the enzyme nitrate reductase and enzyme cofactor 
mixture. This mixture was incubated at room temperature for 1h to allow the 
conversion of nitrate to nitrite. 50 µl each of Griess reagents provided in the 
kit, were added to each well. After colour development for 10 min at room 




spectrophotometer. Nitrate standard curve was used to quantify the nitric oxide 
produced in the samples.  
 
3.25 ELISA Assay for TNF α release 
3.25.1 Principle 
Enzyme-linked immunosorbent assays (ELISAs) is a technique used for 
detecting and quantification of substances such as peptides, proteins, 
antibodies and hormones. ELISAs have proven to be valuable tools for 
detection and quantitation of protein analytes from various biological samples: 
serum, plasma, cell culture supernatants and cell lysates (Engvall and 
Perlmann 1971; Leng et al. 2008).  
 
3.25.2 Materials 
 TNF α ELISA kit (Cat No: 88-7324-22, EBiosciences, USA) 




BV2 cells were plated in 6-well plates and transfected followed by LPS 
treatment, as described above. After 48h, the media supernatants were 
collected, and TNF-α were determined using the EBiosciences ELISA kit that 
specifically recognizes the mouse cytokine TNF-α. On the first day, the wells 
of a 96-well ELISA plate were coated with the capture antibody at 4°C 




with the blocking reagent provided in the kit, followed by addition of 100 µl of 
media supernatant or appropriate dilutions of TNFα standard provided in the 
kit at 4°C overnight. The next day, the detection antibody was added to each 
well and incubated at room temperature for 1h followed by washing and 
colour development. The absorbance was noted at 540 nm and TNF-α standard 
curve was used to calculate the TNF-α level in the samples. 
 
3.26 Cell Migration assay 
3.26.1 Principle 
Cell migration is an important multistep process involved in various processes 
such as development, wound repair and immune surveillance. For quantifiying 
cell migration, cells are seeded on the upper part of a cell permeable 
membrane while a chemoattractant is added to the bottom chamber. Cell 
migration is measured by determining the ability of cells to pass through the 
membrane towards the chemoattractant. The cells that have migrated through 
the membrane are stained and counted.  
3.26.2 Materials 
 Transwell inserts (Corning Life Sciences, MA, USA) 
 100% methanol 
 crystal violet (0.5%) 
3.26.3 Procedure 
BV2 cells were transfected with miR-200b mimics or inhibitors as described 




Transwell inserts (Corning Life Sciences, MA, USA) containing free DMEM 
(no serum). For the control groups, complete medium (10% FBS, DMEM) 
was added to the wells, while for the LPS activated groups, 1mg/ml of LPS 
was added to the wells along with complete medium (10% FBS, DMEM). The 
cells were incubated in the transwell inserts and cultured overnight at 37°C in 
a humidified atmosphere of 5% CO2 and 95% air incubator. Migrating cells on 
the lower membrane surface were fixed with 100% methanol for 15min at 
room temperature while the non migrated cells were scrapped off gently with a 
cotton swab. After washing, the inserts were air-dried. The cells were stained 
with crystal violet (0.5%)/methanol (25%) solution for 30min at room 
temperature. The inserts were then washed in PBS until the blue stain 
lightened followed by air drying. Images were captured on Nikon microscope 
at ×100. Three biological triplicate was performed and ≥5 fields were counted 
from each sample in each experiment. 
 
3.27 Annexin V Apoptosis Assay 
3.27.1 Principle 
Apoptosis is a complex multistep process of cell death. Phosphatidyl serine is 
a phosphoserine membrane component normally expressed on the inner or 
cytosolic surface of the cell membrane of normal live cells. Upon initiation of 
apoptosis, the PS residues are “flipped” and appear on the cell surface. On the 
cell surface, PS can be detected using a protein having high affinity for PS 







 Annexin V-Cy3 Apoptosis Detection Kit (Cat # ab14142, 
Abcam, Cambridge, UK) 
 BD LSRFortessa™ X-20 analyzer (BD Biosciences, San Jose, 
CA, USA) 
3.27.3 Procedure 
Apoptosis assay was carried out using the Annexin V-Cy3 apoptosis detection 
kit. 0.5 × 10
5
 cells were seeded in each well of a 6 well plate followed by 
incubation with a 1:1 mixture of fresh complete medium (1 ml) and 
conditioned medium (1 ml) for 24h. The conditioned medium was obtained 
from untreated BV2 cells and BV2 cells transfected with anti-miR-200b 
(inhibitor) or miR-200b mimics or control probes. Following incubation, the 
cells were gently trypsinized and the staining protocol. Flow-cytometry was 
performed on a BD LSRFortessa™ X-20 (BD Biosciences) analyzer. 
 
3.28 Western blotting 
3.28.1 Principle 
Protein content from a tissue or cell can be quantified using western blot 
technique. The protein samples are separated using poly-acrylamide gel 
electrophoresis followed by transfer on to a polyvinylidene difluoride (PVDF) 
membrane. Primary antibody raised against the protein of interest is used to 
localize the protein. This is followed by using a horseradish peroxidase (HRP) 




substrate for the HRP emits a signal which can be captured onto an X-Ray 
film (Kurien and Scofield 2006).   
3.28.2 Extraction of total protein  
3.28.2.1 Materials 
 Mammalian Protein Extraction Reagent (Prod # 78501, Rockford, MI, 
Thermo Fisher Scientific, USA) 
 Protease Inhibitor (Rockford, MI, Prod # 88665, ThermoFisher 
Scientific, USA) 
 Halt Phosphatase inhibitor cocktail (Part No. 23236, ThermoFisher 
Scientific, USA) 
3.28.2.2 Procedure 
For total protein extraction 200μl of M-PER reagent containing protease and 
phosphatase inhibitor cocktail was added to the cells and incubated for 5min 
on ice. The cells were scrapped out and the resulting lysate was centrifuged at 
14,000 rpm at 4ºC for 20min. the supernatant containing the protein was 
collected in a fresh tube. The protein lysate thus obtained was quantified by 
Bradford assay and stored at -80ºC.  
3.28.3 Extraction of nuclear and cytosolic proteins 
3.28.3.1 Materials 
 Nuclear extraction kit (Cat # 2900, Merck Millipore, Billerica, MA, 
USA) 
3.28.3.2 Procedure 
Total protein was extracted from untransfected BV-2 microglial cells or 




LPS treatments, the cells were trypsinized to collect the cell pellet. The cell 
pellet was incubated on ice for 5min with 150µl of 1X cytoplasmic extraction 
buffer mixed with protease and phosphatase inhibitors followed by pelleting 
the cells again at 250rpm for 5min at 4ºC. The resulting cell pellet was 
resuspended in 60 µl cytoplasmic extraction buffer. Cytoplasmic protein was 
separated by centrifugation at 8000rpm for 20min at 4ºC and collecting the 
resulting supernatant. This was stored at -80ºC. The pellet was resuspended in 
protease and phosphatase inhibitor containing nuclear extraction buffer and 
mixed well using a syringe. Nuclear protein was isolated by centrifuging the 
lysate at 16,000g for 5min at 4ºC and stored at -80ºC.   
   
3.28.4 Estimation of protein concentration 
3.28.4.1 Materials 
 Coomassie Bradford Protein Assay Reagent (Cat # 23200, Bio-Rad, 
CA, USA) 
3.28.4.2 Procedure 
The extracted protein was quantified using the Bradford calorimetric assay 
(Bradford 1976). The Bradford assay is a method to quantify protein using the 
Coomassie Brilliant blue G-250 dye which binds to proteins. Upon binding to 
proteins in the sample, the dye changes colour which can be measured using a 
spectrophotometer at a wavelength of 595nm. BSA standard curve was plot 
using different concentrations of BSA protein (0.006, 0.12, 0.24 and 0.48 
mg/ml) was used to quantify the protein amount in a given sample. 1:10 




well plate and incubated at room temperature for 15 min. The absorbance was 
read at 595 nm and the protein concentration quantified using the equation 
obtained from the standard curve.   
3.28.5 Gel electrophoresis and protein detection 
3.28.5.1 Materials 
10% resolving gel: 
o H2O                                                     4.0 ml 
o 30% acrylamide mix                            3.34 ml 
o 1.5M Tris buffer (pH 8.8)                    2.5 ml 
o 10% SDS                                              100 µl 
o 10% APS                   100 µl 
o T.E.M.E.D                                             5 µl 
 
5% stacking gel:  
o H2O                                                      4.1 ml  
o 30% acrylamide mix                            0.83 ml 
o 1.5M Tris (pH 6.8)                               0.750 ml 
o 10% SDS                                               50 µl 
o 10% APS                                               50 µl 
o TEMED                                                  8 µl 
 Tris/glycine/SDS electrophoresis buffer (Cat # 161-0732EDU, Bio-
Rad, USA) 




 2X Laemmli sample buffer (Cat # 161-0737EDU, Bio-Rad, MO, 
USA) 
 Spectra Multicolor protein ladder (Rockford, MI, Prod # 26634, 
ThermoFisher Scientific, USA) 
 Thick Blot paper (Cat # 170-3931, Bio-Rad, MO, USA) 
 Immun-blot PVDF membrane (Cat # 162-0177, BioRad, MO, 
USA) 
 Clear Milk blocking buffer (Cat # 37587, Pierce, Thermo Scientific 
Fisher, Rockford, MI, USA) 
 Blot qualified BSA (W3841, Promega, WI, USA) 
 Restore PLUS Western Blot Stripping Buffer (Rockford, MI, Prod 
# 46428, ThermoScientific, USA) 
 Goat anti-rabbit HRP antibody (Merck Millipore, Prod # AP307P, 
Billerica, MA, USA) 
 Goat anti-mouse HRP antibody (Merck Millipore, Prod # AP308P, 
Billerica, MA, USA) 
 SuperSignal West Pico Chemiluminescent Substrate (Rockford, 
MI, Prod # 34077, ThermoFisher Scientific, USA) 
 CL-XPosure Film (Rockford, MI, Prod # 34089, Thermo Fisher 
Scientific, USA) 
 Bio-Rad Image Lab TM imaging system (Bio-Rad, MO, USA)  
 1x TBS (pH7.6) 
o Tris base                         2.42 g 




The above salts were mixed in 800 ml of deionised water following which the 
pH was adjusted to 7.6. Finally, the volume was made up to 1liter. 
 1x TBST 
o 1x TBS                              999 ml 
o Tween 20                                1ml 
Table 8: Antibodies used for western blot. 





































Rabbit Sc 20680 
β-actin Sigma-Aldrich Mouse A1978 
 
3.28.5.2 Procedure  
Total protein (40µg) and nuclear protein (20µg) from each sample was mixed 
with laemmli buffer and denatured at 95
0
C for 5min. The denatured protein 
was loaded onto a 10% SDS-PAGE. A protein ladder was run alongside the 
samples for size detection of the proteins. After separation, the proteins were 
transferred on to a PVDF transfer membrane using the semi-dry teansfer 
technique. This was followed by blocking the blots with 5% BSA or 5% milk 
solution for 1h at room temperature. The blots were then incubated with 
appropriate primary antibodies overnight at 4
0
C. The next day after three 
washing steps, the blots were incubated with secondary anti-mouse or anti-
rabbit HRP antibody for 1h at room temperature. Followed by washing with 
TBST, the blots were developed using a chemiluminescence reagent. The 
signal was visualized and quantified using the Bio-Rad Image Lab 
TM 
imaging 
system. All measurements of phosphorylated protein levels were normalized 
by stripping the blots with stripping buffer and reprobing with antibodies 
against total protein. To normalize the protein content of each lane, the blots 




3.29 NFκB Transcription factor assay 
3.29.1 Principle 
The NFκB Transcription factor assay enables sensitive quantification of the 
nuclear translocation of NFκB p65 subunit in nuclear extracts. This assay from 
Merck Millipore is a combination of the electrophoretic mobility shift assay 
(EMSA) with the 96-well plate based enzyme-linked immunosorbant assay 
(ELISA). During the assay, the capture probe, a double stranded biotinylated 
oligonucleotide containing the consenses sequence for NFκB, is mixed with 
nuclear extract in the streptavidin coated plate. When incubated together, the 
NFκB in the nuclear extract binds to the biotinylated consenses sequence and 
is immobilized on the plate. Any unbound material is washed away. The 
bound NFκB is detected with a specific primary antibody. An HRP-conjugated 
secondary antibody is used, which binds to the primary antibody. Addition of 
a substrate for the HRP emits a signal which can be read using a 
spectrophotometer at 450 nm. 
3.29.2 Material 
 Universal EZ-TFA Transcription Factor Assay kit Colorimetri (Cat 
No: 70-500, Merck Millipore, USA) 
 SpectraMax Plus Microplate reader (Molecular Devices, Sunnyvale, 
USA) 
3.29.3 Procedure 
1X Transcription factor assay buffer (TFA) was prepared by diluting 1 part of 




adding blocking reagent to 1X TFA. Following components were added to the 
plate well directly in sequential order- 
 1X Enhanced TFA buffer 
 Oligonucleotide probes 
 Nuclear extract 
This was followed by incubation for 2 hours at room temperature followed by 
3 washes with 1X enhanced TFA. 100µl of 1:1000 diluted primary antibody 
was added to each well followed by incubation for 1 hour at room 
temperature. Unbound primary antibody was washed off with 3 washes of 1X 
enhanced TFA followed by incubation with IgG-HRP conjugated secondary 
antibody for 30 min at room temperature. The wells were then washed with 
1X TFA, 4 times followed by color development using TMB substrate for 10 
min. the absorbance of the samples was measured using a spectrophotometer 
at 450 nm. 
 
3.30 Statistical analysis 
The data were presented as mean ± SD. Three or more biological and technical 
triplicates were used for each experiment. Statistical significance was 
evaluated by the Student’s t- test or ANOVA with post hoc Tukey test. Results 




















4.1 miRNA microarray 
4.1.1 MiRNA expression profile shows that activated microglia are 
biologically distinct from control microglia 
Microglial cells which have amoeboid morphology in the developing brain, 
transform into a branched, ramified morphological phenotype in the adult 
brain (Ling and Wong 1993) (Fig 1 A-B). In the event of pathological insult or 
external stimuli, these microglial cells become activated and morphologically 
hypertrophic with spherical in shape. Primary microglia cultured from rodent 
pup cortices are often used for in vitro studies (Fig 1 C-D). Several studies 
have shown the morphological, molecular and proteomic changes between 
normal and activated microglia (Hurley et al. 1999; Glanzer et al. 2007). In 
the present study, global miRNA expression profiles of control and activated 
primary rat microglia stimulated by LPS or β-amyloid (Aβ) were analyzed. 
Exiqon’s microRNA microarray platform identified a total of 93 miRNAs 
differentially expressed between control and activated rat primary microglia. 
Out of the these 93 miRNAs, top 50 miRNAs having the largest variation 
across control and activated primary microglia were used to generate a 
Principle Component Analysis (PCA) plot. PCA analysis shows that the 
biological difference between the microRNA expression of LPS-treated and 
control microglia is significant as evidenced by the separation of samples in 
different regions of the PCA plot as per their biology (Fig 2). Two illustrations 
of the result of the PCA have been provided: a traditional PCA plot (Fig 2) and 




differences in samples arising due to biological or technical factors. PC1 and 
PC2 describe variation related to sample groups or treatments, whereas PC3 
and later PCs describe underlying or less variable factors like sample 
preparation conditions, operator, storage time etc. Figure 3 shows that the 
control and activated microglia samples show a difference in PC1 and PC2 as 
evidenced by a difference in the color code and thus are biologically distinct. 
 
Fig 1 A-B: Immunofluorescense showing lectin-stained microglia (green, 
arrows) in the corpus callosum of 5 day (A) and 28 day (B) old rat brain. Note 
the change in morphology of microglia from amoeboid (A, arrows) to ramified 
with processes (B, arrows) from early post-natal to adult stage. The nucleus is 




C: Immunofluorescense showing Cd11b-stained primary microglia (green) 
isolated from 3 day old rat pups. The nucleus is counterstained with DAPI 
(blue). Scale bar: 20 μm. 
 
D: Phase contrast image showing primary microglia purified from mixed glial 




Fig 2: Principle Component Analysis (PCA) performed using the top 50 
miRNAs with highest standard deviation, clustered the different samples as 
per their biological differences. The normalized log ratio values have been 
used for the analysis. The mean value across samples is shifted to 0 and the 







Fig 3: Matrix PCA plot. The analysis was performed on all samples, and on 
the top 50 microRNAs with the highest standard deviation. The normalized 
log ratio values have been used for the analysis. The mean value across 




4.1.2 Activated microglia show distinct miRNA expression pattern  
The miRNA signature of activated primary microglia was characterized using 
global miRNA profiling. 93 miRNAs were identified to be differentially 




Fig 4: The heat map diagram shows the result of a two-way clustering of 
miRNAs and samples. Each column represents a biological sample while each 
row represents a miRNA. The miRNA clustering tree is shown on the left. The 
colour scale represents the relative expression level of each miRNA in each 
sample as compared to the reference channel. Red colour indicates an 
expression that is below the reference channel, while green colour indicates an 
expression that is higher than the reference. 
 
 
A volcano plot drawn comparing the expression profile between control and 
LPS activated microglia (Fig 5) identified members of miRNA -29, -30 and -
101 families as most differentially expressed. Sheet 2 lists the differentially 




Fig 5: Volcano plot illustrating the relation between the logarithm of the p-




and LPS-activated microglia. The top selected miRNAs are marked with 
annotation on the plot and tabulated on the right.  
 
Although a large fold change difference was not observed in the Aβ - activated 
microglia as compared to control, miRNAs-21, -485, -370 were identified as 





Fig 6: Volcano plot illustrating the relation between the logarithm of the p-
values and the log fold change of miRNAs differentially expressed in control 
and Aβ-activated microglia. The top selected miRNAs are marked with 








Further, a comparison between LPS- and A-activated microglia revealed 




Fig 7: Volcano plot illustrating the relation between the logarithm of the p-
values and the log fold change of miRNAs differentially expressed between 
LPS- (left) and A- (right) activated microglia. The top selected miRNAs are 
marked with annotation on the plot. 
 
Certain miRNA families were also found to be commonly expressed by both 
groups (Sheet 5). Thus, this analysis revealed that activation of microglia (by 
LPS and A) as observed in neuroinflammation and neurodegenerative 




group of miRNAs possibly leading to altered gene expression and 
subsequently perturbed function of microglia in the CNS pathologies. 
 Selected common miRNAs from the LPS and Aβ activated microglia from the 
microarray were validated in primary microglia culture by qRTPCR (Fig 8). 
The PCR products were run on a 15% native PAGE to check for the presence 
of a single product indicating primer specificity. qRTPCR results for LPS 
activated microglia were consistent with the results obtained from the miRNA 
microarray. However a disparity was observed in the A group. Hence further 

























































Fig 8 A: qRT-PCR analysis in control, A and LPS activated primary 
microglia. Results are represented as miRNA fold change with respect to 
untreated controls. Statistical analysis was carried out using ANOVA with 
post-hoc Tukey test. Data represent the mean + SD (n=5) **p<0.01; *p<0.05. 
 




4.1.3 Pathway analysis predicts miRNAs targeting TGF-Smad2 
pathway in activated microglia 
Ingenuity pathway analysis (IPA) software was employed to identify the 
signaling pathways targeted by miRNAs that were found to be differentially 
expressed in activated microglia. A comparison between LPS-activated and 
control microglia groups predicted several miRNAs targeting different 
members of the TGF-SMAD pathway, including TGF2 and TGF3, TGF 
receptors 1 and 2 (TR1 and TR2), several transcription factors belonging to 




targeted by the selected miRNAs have been listed in sheet 6. Among other 
miRNAs, miR-27a was predicted to target 7 members of this family including 
TR1, SMAD2 and Runx1. Another bioinformatic search using the 
miRWALK software confirmed these genes as the putative targets of miR-27a. 
Given the upregulation of miR-27a in LPS-activated microglia along with the 
prediction of several genes of the TGF-SMAD pathway (which has been 
shown to exhibit anti-oxidative and anti-inflammatory effects) to be targeted 
by this miRNA, miR-27a was chosen for further studies with the pathway of 
choice highlighted in Fig 10 (Hu et al. 1995; Paglinawan et al. 2003; Kim, 





Fig 9: pathway generated using IPA software with selected miRNAs from the 









Fig 10: TGFβ pathway selected for analysis highlighting miR-27a targeting 







4.2 MiR-27a targets TGFβ signalling pathway in microglia 
4.2.1 MiR-27a is upregulated in activated microglia in vitro  
Quantitative RTPCR analysis revealed that expression of miR-27a is 





Fig 11 A: qRT-PCR analysis revealing increase in miR-27a expression in LPS 
(black) and Aβ (shaded) activated BV2 microglia. Results are represented as 
miRNA fold change with respect to untreated controls. Statistical analysis was 
carried out using ANOVA with post-hoc Tukey test. Data represent the mean 
+ SD (n=6) ***p<0.001.  
 
B: 15% native PAGE showing the band for miR-27a following amplification. 
 
4.2.2 MiR-27a expression is upregulated in microglia in vivo in 
Traumatic brain injury model 
In the present study, rat TBI model has been used to study microglia-mediated 
neuroinflammation, which exaggerates neuronal cell death in the regions of 
hippocampus thus contributing to increased cognitive dysfunction (Morganti-
Kossmann, M.C.; 2007). After inducing TBI, microglial activation after 
neuronal damage in the hippocampal brain sections in comparison to sham 
(control) operated animals was confirmed by the induced expression of iNOS 
(Fig 12 Aa-Bc).  
Microglia cells were detected in the hippocampus of sham-operated and 
TBI rat brain sections using lectin as the marker and isolated by laser capture 
microdissection (Fig 12 C-F). The cells isolated by LCM were confirmed to be 




(Cd11b), but not oligodendrocyte (CNPase), astrocyte (GFAP), neuronal 
(MAP2) and endothelial (PECAM-2) specific genes (Fig 12 G). MiR-27a 
expression was also observed to be upregulated in laser capture microdissected 
microglia from traumatic brain injury (TBI) model. This analysis revealed that 
miR-27a is upregulated in activated microglia both in vitro and in vivo (Fig 12 
H).  
 
Fig 12 Aa-Bc: Confocal images showing iNOS expression (red) in microglia 
(green) in the hippocampus of 2-month old sham operated (Aa-Ac) and TBI 
(Ba-Bc) rat brain by immunofluorescense.  Note the expression of iNOS (Bb-
Bc, arrows) in microglia after TBI. The nucleus is counterstained with DAPI 







Fig 12 C-F: Light microscopy images showing microglia stained with lectin in 
the hippocampus of sham operated (C-D) and TBI (E-F) rat brain respectively. 
Figure C, E show microglia before laser capture microdissection. Figures D 
and F which are the same sctions shown in Fig C and E respectively, show the 
stained cells that have been laser cut by laser capture microdissection. Scale 
bars C-F: 50 µm  
 
G: Agarose gel image showing the semi-quantitative PCR of oligodendrocyte 
(CNPase), astrocyte (GFAP), neuronal (MAP2) and endothelial cell-specific 








Fig 12 H: qRT-PCR analysis revealing increase in miR-27a expression in 
LCM extracted activated microglia from TBI model. Results are represented 
as miRNA fold change with respect to sham-operated control. Statistical 






4.2.3 TGFβ is upregulated in activated microglia in vivo 
 
TGFβ expression was observed in microglia in the corpus callosum of 5-day 
old rat pup by immunoflourescence (Fig 13 A-C). An increase in TGFβ 









Fig 13 A-F: Confocal images showing TGFβ expression (red) in lectin stained 
microglia (green) in the corpus callosum of 5-day old control (A-C) and LPS 
injected (D-F) rat brain by immunofluorescense. Note the increase in TGFβ 
expression in activated microglia (E-F, arrows).  The nucleus is counterstained 
with DAPI (blue) Scale bar: 20 μm. 
 
 
4.2.4 Inverse relationship between miR-27a and its targets SMAD2 and 
TR1 in activated microglia 
IPA predicted miR-27a to target SMAD2 and TR1. This analysis was 
confirmed using the bioinformatic tool miRWALK (Fig 14 A, B).  qRT-PCR 




activated primary and BV2 microglia exposed to LPS for 1 to 6h. Conversely 
down-regulation of SMAD2 and TR1 mRNA expression was observed in 
primary and BV2 microglia exposed to LPS (1µg/ml) for 1 to 6h, indicating an 
inverse relationship between miR-27a and its target expression in activated 





Fig 14 A-B: Alignment of TR1 3’UTR (A), SMAD2 3’UTR (B) with seed 








Fig 14 C-D: miR-27a, SMAD2 and TβR1 expression was quantified using 
qPCR in primary microglia (C) and BV2 microglia (D) after 1-6h of LPS 
activation revealing increase in miR-27a expression and decrease in SMAD2 












4.2.5 SMAD2 expression is downregulated in activated microglia in vitro 
 It has been shown that in response to stimulus, SMAD2 is phosphorylated at 
its carboxy terminus on residue Ser465/467 by TGF receptor R1, leading to 
its activation and nuclear transport (Massagué 2000; Khalil et al. 2001; 
Massagué et al. 2005).  Immunocytochemical analysis showed the expression 
of total and phospho-SMAD2 in BV2 microglia. The expression of phospho-
SMAD2 was observed only on activation of BV2 microglia with TGF1 
cytokine indicating that SMAD2 is activated only in response to TGF 
signaling in microglia (Fig 15 A-D). A cytoplasmic localisation of total 
SMAD2 was observed in untreated control microglia. Treatment of microglia 
with human recombinant TGF1 led to an increase in the expression of 
nuclear SMAD2. Moreover, inhibition of TGF signaling by pretreatment of 
cells using the TR1 receptor inhibitor, SB 431542 led to a decrease in 







Fig 15 A-D: Immunocytochemistry showing the expression of p-SMAD2 
(red) (A-D) after TGFβ1 treatment of BV2 microglia. p-SMAD2 expression is 
absent in control (A), LPS activated (B) or SB 431542 treated (D) BV2 
microglia. Note the expression of phospho-SMAD2 only after TGFβ1 
treatment of BV2 microglia (C). The nucleus is counterstained with DAPI 







Fig 15 E-H: Immunocytochemical analysis showing total SMAD2 expression 
in red (E-H). Nuclear expression of total-SMAD2 is observed after TGFβ1 
treatment of BV2 microglia (red, G) whereas cytoplasmic expression of total-
SMAD2 is observed in control (E), LPS-treated (F) and SB 431542 (H) treated 







qRTPCR analysis of SMAD2 in primary microglia revealed its mRNA 
expression decreasing on LPS activation of microglia. SMAD2 mRNA 
expression was observed to be increased in primary microglia following 
TGF1 treatment, while the expression was decreased in cells pretreated with   
SB 431542, TR1 receptor inhibitor (Fig 16 A). Similarly, western blot 
analysis in primary microglia indicated an upregulation of SMAD2 protein 
expression after TGF1 treatment and down regulation of SMAD 2 after 
treatment of SB 431542 (Fig 16 B-C). 
 
 
Fig 16 A: qPCR analysis reveals increase in mRNA expression of SMAD2 in 
primary microglia after treatment of TGFβ1 and SB 431542. Results are 
represented as mRNA fold change with respect to control. Statistical analysis 
was carried out using ANOVA with post-hoc Tukey test. Data represent the 





B-C: Quantification of protein expression of SMAD2 after western blot 
reveals an upregulation in expression after TGFβ1 treatment of primary 
microglia. Statistical analysis was carried out using ANOVA with post-hoc 
Tukey test. Data represent the mean + SD (n=4) *p<0.05. 
 
4.2.6 Nuclear translocation of SMAD2 observed in activated microglia 
in vivo  
SMAD2 expression was observed in microglia in the corpus callosum of 5D 
old rat pup by immunoflourescence (Fig 17 A-C). The SMAD2 expression 
appeared to translocate to the nucleus upon LPS activation of microglia in vivo 
(Fig 17 D-E). 
 
Fig 17 A-F: Confocal images showing the expression of total SMAD2 (red) in 
microglia (green) distributed in the corpus callosum of 5D pup control (A-C), 
and LPS injected (D-F) by immunofluorescense. Note the nuclear 
translocation of SMAD2 upon activation of microglia (E-F, arrows). The 






4.2.7 TR1 expression is downregulated in activated microglia in vitro 
Confirming with previously published reports, a cytoplasmic expression of 
TR1 was observed both in primary and BV2 microglia (Fig 18 A-P). Upon 
LPS activation, a decrease in TR1 expression was observed in primary and 
BV2 microglia. However treatment of cells with TGF1 led to an increase in 
TR1 expression which was reduced on pretreatment of the cells with the 
TR1 inhibitor SB 431542. qRTPCR analysis revealed a significant decrease 
in TR1 expression on primary microglia exposed to LPS. This expression 
peaked upon TGF1 treatment followed by a decline after pretreatment of the 
cells with SB 431542 (Fig 18 Q). Similarly western blot analysis revealed a 
decrease in  TR1 protein expression in LPS activated primary microglial cells 
while an upregulation was observed after TGF1 treatment of primary 
microglia followed by a significant decline in its expression upon pretreatment 











Fig 18 A-S: Confocal images showing TR1 expression (red) in primary 
microglia (green) stained with Cd11b (A-L), and BV2 microglia marked with 
lectin (green) (M-P). The nucleus is counterstained with DAPI (blue) Scale 
bar: 40 μm.  
Q qPCR analysis reveals increase in mRNA expression of TβR1 after TGFβ1 
treatment of primary microglia. Statistical analysis was carried out using 
ANOVA with post-hoc Tukey test. Data represent the mean + SD (n=4) 
***p<0.001, **p<0.01, *p<0.05. 
R-S. Quantification of protein expression of TβR1 after western blot reveals 
an upregulation of TR1 expression after TGFβ1 treatment of primary 
microglia. Statistical analysis was carried out using ANOVA with post-hoc 






4.2.8 TR1 expression is unaltered in activated microglia in vivo 
TR1 expression was observed in microglia in the corpus callosum of 5-day 
old rat pup by immunoflourescence (Fig 19 A-C). However no change in 




Fig 19 A-F: Confocal images showing the expression of TR1 (red) in lectin 
stained microglia (green) from corpus callosum of 5-day old rat pup control 
(A-C) and LPS injected (D-F) brain. Significant change in TR1 expression 
was not observed after LPS activation of microglia in vivo. The nucleus is 






4.2.9 MiR-27a targets SMAD2 and TR1 in microglia 
Functional analysis of miR-27a in microglia was carried out using miR-27a 
inhibitor and miR-27a mimic to mimic knockdown and overexpression of 
miR-27a in BV2 microglia, respectively. MTS cell viability assay revealed 
that there was no significant cell death 24h after transfection (Fig 20 A). 
Knockdown of miR-27a in BV2 microglia revealed an increase in SMAD2 
and TR1 mRNA and protein expression (Fig 20 B-F). On the other hand, 
overexpression of miR-27a led to a decrease in the protein expression of 
SMAD2 and TR1 (Fig 20 B-F) indicating that these genes are targeted by 






Fig 20 A: MTS assay following miR-27a transfection showed that there was 
no significant cell death. Statistical analysis was carried out using ANOVA. 
Data represent the mean + SD (n=5).  
 
B: SMAD2 mRNA expression was quantified following knockdown and 
overexpression of miR-27a. The results indicate an increase in SMAD2 
expression after miR-27a knockdown. 
 
C: TβR1 mRNA expression was quantified following knockdown and 
overexpression of miR-27a.  The results indicate an increase in 
TβR1expression after miR-27a knockdown. 
 
D. Western blot analysis of SMAD2 and TβR1 protein expression after 
knockdown and overexpression of miR-27a.  
 
E: Quantification of SMAD2 protein expression using densitometry analysis 
showing an increase in SMAD2 protein expression after knockdown and 
overexpression of miR-27a. Statistical analysis was carried out using 
ANOVA. Data represent the mean + SD (n=4) ***p<0.001, **p<0.01, 
*p<0.05. 
 
F: Quantification of TβR1 protein expression using densitometry analysis 
showing an increase in TβR1 protein expression after knockdown and 
overexpression of miR-27a. Statistical analysis was carried out using 








4.2.10 SMAD2 activity is altered by miR-27a in BV2 microglia 
The function of SMAD2 is dependent upon its phosphorylation and thereby 
activation in response to TGF signaling. Hence, SMAD2 activity was 
evaluated by checking its phosphorylation status after miR-27a knockdown 
and overexpression in TGFβ treated-BV2 microglia. Western blot analysis 
revealed an increase in phospho-SMAD2 expression after miR-27a 
knockdown in TGFβ treated-BV2 microglia (Fig 21 A, C). Conversely a 
decrease in phospho-SMAD2 expression was observed after miR-27a 
overexpression in TGFβ treated-BV2 microglia (Fig 21 B, C) indicating that 






Fig 21 A-B: Western blot of phospho- and total SMAD2 after miR-27a 
knockdown (A) and overexpression (B) in TGFβ-treated BV2 microglia. Note 
the expression of phospho-SMAD2 only after TGFβ treatment in microglia.  
 
C. Quantification of phospho-SMAD2 protein expression using densitometry 
analysis showing an increase in phospho-SMAD2 protein expression after 
knockdown of miR-27a in BV2 microglia.  Statistical analysis was carried out 
using ANOVA. Data represent the mean + SD (n=4),*p<0.05. 
 
 
4.2.11 Runx1 is upregulated in activated microglia in vitro and in vivo 
Runx1 was identified as the final target of miR-27a in the TGF signaling 
pathway. Immunocytochemical analysis revealed an increase in the protein 
expression of Runx1 in both TGF-treated as well as LPS-activated BV2 
microglia. There was a decrease in Runx1 expression upon blockade of TGF 
signaling by SB 431542, indicating that Runx1 is a target of TGF pathway in 
BV2 microglia (Fig 22 A-D). Moreover, qPCR analysis in primary microglia 
confirmed these findings with an increase in Runx1 mRNA expression after 
activation of microglia with LPS as well as TGF. However, Runx1 
expression was found to be decreased followed pre-treatment of BV2 
microglia with SB 431542 (Fig 22 E). Further a time-dependent up-regulation 
of Runx1 expression was observed in primary microglia exposed to LPS 
(1µg/ml) for 1 to 6h. Maximal Runx1 expression was observed at 3h of LPS 
exposure in primary microglia (Fig 22 F). Runx1 expression was also 
observed to be upregulated in laser capture microdissected microglia from 
traumatic brain injury (TBI) model (Fig 22 G). This analysis revealed that 









Fig 22: A-D Immunocytochemistry showing increase in Runx1 expression 
(red) in LPS and TGFβ1 activated BV2 microglia (B, C, red). The cells are 
marked with lectin (green) and nucleus is counterstained with DAPI (blue). 







Fig 22 E. qPCR analysis of Runx1 expression showing an increase in LPS and 
TGFβ1 activated primary microglia and a decrease on SB 431542 pre-
treatment of primary microglia. Statistical analysis was carried out using 
ANOVA. Data represent the mean + SD (n=4), ***p<0.001, **p<0.01, 
*p<0.05. 
 
F. qPCR analysis showing an increase in Runx1 mRNA expression in time 
course of LPS activated primary microglia from 1-6h. Statistical analysis was 
carried out using ANOVA. Data represent the mean + SD (n=3), ***p<0.001, 
**p<0.01, *p<0.05 
G. qPCR analysis of Runx1 in LCM-extracted microglia from TBI model. 
Statistical analysis was carried out using ANOVA. Data represent the mean + 





4.2.12 MiR-27a targets Runx1 in microglia 
Targetscan website shows Runx1 harbouring two conserved miR-27a binding 
sites in its 3’UTR (Fig 23 A). MiR-27a gain-of-function analysis in BV2 
microglia revealed a downregulation of Runx1 mRNA and protein expression 
after miR-27a overexpression (Fig 23 B-D). Moreover, TGFβ treatment failed 
to produce a significant increase in Runx1 protein expression after miR-27a 
overexpression (Fig 23 C-D). Conversely, increase in Runx1 protein was 





Fig 23 A: Alignment of Runx1 3’UTR with miR-27a seed region obtained 
from Targetscan website. 
 
B. Runx1 mRNA expression was quantified following knockdown and 
overexpression of miR-27a using qPCR analysis. The results show a decrease 
in mRNA expression after miR-27a overexpression. Statistical analysis was 







Fig 23 C-D. Densitometry analysis and western blot of Runx1 protein 
expression after miR-27a overexpression showing a decrease in Runx1 protein 
expression after miR-27a overexpression in untreated and TGFβ1 treated BV2 
microglia. Statistical analysis was carried out using ANOVA. Data represent 
the mean + SD (n=3), *p<0.05. 
 
E-F. Densitometry analysis and western blot of Runx1 protein expression after 
knockdown of miR-27a showing an increase in Runx1 protein expression after 
miR-27a knockdown. Statistical analysis was carried out using ANOVA. Data 





4.2.13 Overexpression of miR-27a increases expression of 
proinflammatory markers/classical activation markers in activated 
microglia 
MiR-27a was overexpressed in BV2 microglia to check the expression of the 
proinflammatory cytokines TNF, IL6, IL-1 and the NO pathway enzyme 
iNOS. The expression of iNOS was significantly upregulated at the protein 
level after miR-27a overexpression as compared to control miR+LPS group as 
evaluated by immunocytochemistry (Fig 24 A-H). Activation of BV2 
microglia with LPS led to a significant increase in the mRNA expression of 
TNF, IL6, IL-1 and iNOS. The expression of these proinflammatory 
markers was further enhanced upon miR-27a overexpression followed by 
activation of BV2 microglia as compared to activated microglia transfected 
with control mimic (Fig 24 I-L). Further, the TNFα released in the medium by 
activated microglia was measured using ELISA showing an increase in TNFα 
release after miR-27a overexpression as compared to control miR (Fig 24 M, 
grey bars), whereas, a decrease in TNFα release was observed after miR-27a 














Fig 24 A-D: Confocal images showing the expression of iNOS (red) after 
miR-27a overexpression in BV2 microglia. The nucleus is stained with DAPI 
(blue) Scale bar: 20 μm Note the increase in iNOS expression in activated 
BV2 microglia after miR-27a overexpression (D) as compared to control 








Fig 24 G-H: Confocal images showing the expression of iNOS (red) after 
miR-27a knockdown in BV2 microglia. The nucleus is stained with DAPI 
(blue) Scale bar: 20 μm Note the decrease in iNOS expression in activated 









Fig 24 I-L: qPCR analysis showing an increase in  TNFα (I), IL6 (J), IL-1β 




Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=4), **p<0.01, *p<0.05. 
 
M: ELISA to measure TNFα protein release in media shows an increase in 
TNFα release after miR-27a overexpression in activated BV2 microglia.   
Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=4), ***p<0.001, **p<0.01, *p<0.05.  
 
N: ELISA to measure TNFα protein release in media shows a decrease in 
TNFα release after miR-27a knockdown in activated BV2 microglia. 
Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=4), ***p<0.001, **p<0.01, *p<0.05. 
 
 
4.2.14 Inhibition of TGF signaling by miR-27a in microglia leads to 
suppression of anti-inflammatory/alternative activation markers  
Evaluation of expression of alternative activation markers Arginase1 and YM1 
revealed an increase in the expression of these genes after treatment of BV2 
microglia with recombinant TGF1 (Fig 25 A-B). However overexpression of 
miR-27a followed by treatment of BV2 microglia with recombinant TGF1 
led to a significant decrease in the expression of these genes as compared to 
control group treated with LPS. On the other hand, there was a further increase 
in the expression of Arg1 and YM1 after knockdown of miR-27a and 







Fig 25 A: qPCR analysis showing an increase in arginase1 expression after 
miR-27a knockdown in TGFβ1 treated BV2 microglia (light bars) and 
decrease in arginase1 mRNA expression after miR-27a overexpression in 
TGFβ1 treated BV2 microglia (dark bars). Statistical analysis was carried out 
using ANOVA with post-hoc Tukey test. Data represent the mean + SD (n=4), 





B: qPCR analysis showing an increase in YM1 expression after miR-27a 
knockdown in TGFβ1 treated BV2 microglia (light bars) and decrease in YM1 
mRNA expression after miR-27a overexpression in TGFβ1 treated BV2 
microglia (dark bars). Statistical analysis was carried out using ANOVA with 
post-hoc Tukey test. Data represent the mean + SD (n=4), **p<0.01, *p<0.05. 
 
4.2.15 MiR-27a knockdown blocks NFB nuclear translocation in 
activated microglia 
Activation of microglia in response to a stimulus results in the upregulation of 
the transcription factor, NFB which is translocated to the nucleus to activate 
the transcription of several inflammatory genes (Brasier 2006; Gilmore 2006). 
Thus, NFB nuclear translocation is an important aspect of inflammatory 
processes. Immunocytochemistry analysis revealed nuclear translocation of 
NFB upon LPS activation of BV2 microglia (Fig 26 B, G). Moreover 
increased translocation of NFB was observed on miR-27a overexpression in 
activated BV2 microglia (Fig 26 A-D). This observation was confirmed using 
ELISA which detected an increased amount of NFκB p65 subunit in the 
nuclear extract after miR-27a overexpression in activated BV2 microglia as 
compared to control miR + LPS group (Fig 26 E). Conversely NFB nuclear 
translocation was inhibited on miR-27a knockdown in activated BV2 
microglia (Fig 26 F-I). Also, a decrease in the NFκB p65 subunit was observed 
by ELISA in nuclear extract isolated after miR-27a knockdown in activated 









Fig 26 A-D: Immunocytochemistry showing the expression of NFκB (red) 
after miR-27a overexpression Note the increase in NFκB translocation in 
activated microglia after miR-27a overexpression (D) as compared to control 
mimic (B). The nucleus is stained with DAPI (blue) Scale bar: 20 μm. E: 
Quantification of nuclear translocation of NFκB p65 subunit using ELISA 
showing an increase after miR-27a overexpression as compared to control 
miR in LPS activated BV2 microglia. Statistical analysis was carried out 
using ANOVA with post-hoc Tukey test. Data represent the mean + SD 








Fig 26 F-I: Immunocytochemistry showing the expression of NFκB (red) 
after miR-27a knockdown in BV2 microglia. Note the decrease in NFκB 
translocation in activated microglia after miR-27a knockdown (I) as 
compared to scrambled control (G). The nucleus is stained with DAPI (blue) 
Scale bar: 20 μm. J: Quantification of nuclear translocation of NFκB p65 
subunit using ELISA, showing a decrease after miR-27a knockdown as 
compared to scrambled miR in LPS activated BV2 microglia. Statistical 
analysis was carried out using ANOVA with post-hoc Tukey test. Data 
represent the mean + SD (n=3), ***p<0.001, **p<0.01, *p<0.05. 
 
4.2.16 MiR-27a knockdown in microglia decreases neuronal apoptosis 
Effect of miR-27a modulation in microglia on neuronal survival was examined 
using MN9D neuronal cells.  MN9D cells were treated with BV2 conditioned 
medium and neuronal cell death was assessed using Annexin V FACS 
analysis. Apoptosis was observed in neuronal cells treated with conditioned 
medium (CM) obtained from LPS-activated BV2 microglia transfected with 




mimic) (Fig 27 A-C). There was a further increase in number of apoptotic 
cells exposed to CM obtained from miR-27a overexpressing BV2 microglia as 
compared to control + LPS-treated BV2 microglia (Fig 27 A, C). Conversely, 
a decrease in apoptotic neuronal cells was observed in culture containing CM 
obtained from LPS-activated microglia with miR-27a knockdown as compared 








Fig 27 A-B: FACS analysis of annexin V stained apoptotic MN9D neurons 
after miR-27a overexpression (A) and miR-27a knockdown (B).  
 
C. Quantification of apoptotic MN9D cells assessed using annexin V FACS 
indicates a decrease in neuronal apoptosis after miR-27a knockdown as 
compared to scrambled miR (white bars) and increased neuronal apoptosis 
after miR-27a overexpression as compared to control miR (red bars). 
Statistical analysis was carried out using ANOVA. Data represent the mean + 





4.3 MiR-200b targets cJun/MAPK pathway in microglia 
 
4.3.1 MiR-200b is localized in microglia  
In situ hybridization was carried out using a 5’-FITC tagged LNA probe 
specific for the mature form of miR-200b. U6 was used as a positive control 
for the experiment (Fig 28 B). The expression of miR-200b was observed in 
the cytoplasm of BV2 microglia (Fig 28 C) and primary microglial cells (Fig 







Fig 28 A-D: in situ hybridization analysis using 5’ fluorescently labeled 
scrambled microRNA probe (A), U6 reference small RNA (B), mmu-miR-
200b in BV2 microglia (C) and primary microglial cells (D) (green). Note the 
expression of miR-200b in the cytoplasm of BV2 and primary microglia.The 
nucleus is counterstained with DAPI (DAPI – blue). Scale bars A-D: 20 µm. 
 
 
4.3.2 MiR-200b expression is altered in activated microglia 
A time-dependent down-regulation of miR-200b expression was observed in 
BV2 microglia exposed to LPS (1µg/ml) for 1 to 6h, indicating that miR-200b 
expression is altered in activated microglia (Fig 29 A). The PCR products 
were run on a 15% native PAGE to check for the presence of a single product 
indicating primer specificity. 
 
 
Fig 29 A: miR-200b expression was quantified using Real Time PCR analysis 
using LNA primers specific for mmu-miR-200b revealing decrease in 
expression for time course of LPS treatment of 1-6h in BV2 microglia. 
Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=4) **p<0.01; *p<0.05. 
 






4.3.3 cJun expression is upregulated in activated microglia 
MiR-200b was predicted to target members of the MAPK signalling pathway 
(Juhila et al. 2011). Among the target genes predicted, the transcription factor, 
cJun, was chosen due to its role in inflammatory response of microglia via 
MAPK signaling pathway. cJun is tightly regulated post-translationally and is 
phosphorylated in two distinct regions. Activation of cJun occurs by 
phosphorylation at serine 63 and 73 located at the N terminal (Pulverer et al. 
1991). Immunocytochemistry analysis revealed an increase in cJun 
phosphorylation and total protein in activated BV2 microglia (Fig 30 A-D). 
The mRNA expression level of cJun was evaluated in BV2 microglia after 
different time points of LPS exposure. cJun expression was greatly enhanced 
in BV2 microglia at 1h after activation and remained upregulated upto 6h of 
LPS treatment (Fig 30 D) indicating an inverse relationship between cJun and 

































Fig 30 A-D. Immunocytochemistry revealing the increase in phospho cJun (A, 
B, red) and total cJun (C, D, red) expression after activation of BV2 microglia. 
The cells are marked with lectin (green) and the nucleus is counterstained with 
DAPI (DAPI – blue). Scale bars A-D: 50 µm. 
  
E. cJun mRNA expression was quantified using Real Time PCR analysis after 
1-6h of LPS activation. Results are represented as mRNA fold change with 
respect to untreated controls. Statistical analysis was carried out using 




4.3.4 MiR-200b expression is downregulated in microglia in vivo in 
traumatic brain injury rat model  
qRT-PCR analysis revealed a down-regulation of miR-200b expression in 
activated microglia in vivo in LCM-extracted microglial cells from TBI injury 
model (Fig 31). On the other hand, miR-200b putative target gene, cJun 
exhibited increased mRNA expression in microglia following TBI (Fig 31). 
These results confirmed an inverse correlation between the expression of miR-




































Fig 31: qPCR analysis indicates decrease in miR-200b expression and 
increase in activated microglia in vivo from TBI model using LCM. Statistical 
analysis was carried out using Student’s t-test. Results are represented as 
miRNA/mRNA fold change with respect to untreated controls. Data represent 
the mean + SD (n=4) **p<0.01; *p<0.05. 
 
 
4.3.5 MiR-200b binds to the 3’UTR of cJun in microglia  
 To assess whether cJun is a direct target of miR-200b, a luciferase reporter 
assay was carried out. cJun 3’UTR was cloned into the pMirTarget reporter 
vector. RFP expression from the pMirTarget reporter was used for assessing 
transfection efficiency (Fig 32 A-D). Co-transfection of BV2 cells with miR-
200b mimics and the reporter plasmid containing cJun 3’ UTR resulted in a 
significant decrease in luciferase activity as compared to control mimics 






Fig 32 A,C. Confocal images showing the expression of red fluorescent 
protein  (RFP) in BV2 cells co-transfected with control mimic and pMirTarget 
reporter vector containing mouse cJun 3’UTR (A) and BV2 cells co-
transfected with miR-200b mimic and pMirTarget reporter vector containing 
mouse cJun 3’UTR (C).  
 
B,D. Phase contrast images of BV2 cells co-transfected with control mimic 





cells co-transfected with miR-200b mimic and pMirTarget reporter vector 
containing mouse cJun 3’UTR (D).  
 
E. Luciferase activity assay using reporter pMirTarget with mouse cJun 3′ 
UTR was performed after co-transfection with miR-200b mimic or control 
mimic in BV-2 cells. The luciferase activity of the control mimic transfection 
was set to 1. Low luciferase activity as compared to control after miR-200b 
overexpression indicates binding of miR-200b to cJun 3’UTR. Statistical 
analysis was carried out using Student’s t-test. Mean ± SD (n=5), *p<0.05. 
 
 
4.3.6 MiR-200b targets cJun in microglia  
Gain- and loss-of-function analysis was carried out to substantiate the 
luciferase assay result. MiR-200b was knocked down using miRCURY 
LNA
TM
 miR-200b inhibitor while miR-200b was overexpressed using miR-
200b mirVana™ mimic, respectively in BV2 microglia (Fig 33 A). MTS assay 
performed to check cell viability did not show significant cell death 24h after 
transfection (Fig 33 B). Knockdown of miR-200b resulted in a significant 
increase in expression levels of cJun mRNA and total protein (Fig 33 C-E). 
Conversely overexpression of miRNA-200b resulted in a significant decrease 
in cJun expression at the protein level (Fig 33 D-E). Taken together, these 







Fig 33 A. Confocal image (transmission) showing anti-miR-200b probe 
tagged with fluorophore- FITC. Majority of the cells show localization of the 
probe indicating high efficiency of transfection. Scale bar: 50 µm. 
  
B. MTS assay showing no change in cell viability after miR-200b inhibition 
and miR-200b overexpression indicating low cell death after these treatments.  
 
C. cJun mRNA expression in BV2 cells quantified using qPCR showing an 
increase in expression following knockdown of miRNA- 200b. Statistical 
analysis carried out using Student’s t-test. Results are represented as mRNA 
fold change with respect to untreated controls. Mean ± SD (n=5), *p<0.05.   
 
D-E. cJun protein expression after miR-200b knockdown and overexpression 
was quantified using densitometry analysis following western blot indicating 
an increase in cJun protein expression following miR-200b knockdown and 
decrease in expression after miR-200b overexpression. Results are represented 
as protein fold change with respect to untreated controls. Statistical analysis 






4.3.7 Knockdown of miR-200b increases cJun phosphorylation in LPS-
activated BV2 microglia 
cJun activity was assessed by examining its phosphorylation status. Western 
blot analysis confirmed an increase in cJun phosphorylation in BV2 microglia 
after LPS treatment (Fig 34 A-D). There was a further increase in phospho-
cJun after knockdown of miR-200b in activated microglia (Fig 34 A-B). 
Conversely overexpression of miR-200b did not increase the phosphorylation 
of cJun significantly in activated microglia (Fig 34 C-D). These results 
demonstrate that targeting of cJun by miR-200b in microglia is functionally 
relevant since cJun activity (phosphorylated levels) was altered by miR-200b 






Fig 34 A-B: Activation of cJun in nuclear extracts of activated BV2 microglia 
was measured by western blotting using antisera against phosphorylated (p) 
and total cJun and quantified using densitometry analysis shows an increase in 
phospho-cJun after miR-200b knockdown in activated BV2 microglia.  
Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=5), *p<0.05  
 
C-D: Activation of cJun in nuclear extracts of activated BV2 microglia was 
measured by western blotting using antisera against phosphorylated (p) and 
total cJun and quantified using densitometry analysis shows a decrease in 
phospho-cJun after miR-200b overexpression in activated BV2 microglia.  
Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=5), *p<0.05. 
 
 
4.3.8 MiR-200b suppresses JNK activity by downregulating cJun 
expression 
JNKs, members of the MAPK signaling molecules, bind and phosphorylate c-
Jun (Hibi et al., 1993). In the present study we examined if suppression of 
cJun expression by miR-200b alters the JNK protein activity. The expression 
levels of total-JNK and phospho-JNK protein were examined by western blot 
after miR-200b knockdown and overexpression in BV2 microglia. JNK 
activity increased in activated microglia transfected with scrambled miRNA 
and control mimic (Fig 35 A-D). MiR-200b knockdown further increased the 
JNK phosphorylation in activated BV2 cells as compared to scrambled 
miRNA (Fig 35 A-B). Conversely overexpression of miR-200b decreased 
JNK phosphorylation in activated BV2 cells, as compared to control activated 
cells confirming the alteration of JNK activity concomitant with cJun activity 






Fig 35 A-B: Activation of JNK in activated BV2 microglia measured by 
western blotting using antisera against phosphorylated (p) and total JNK and 
quantified using densitometric analysis shows an increase in phospho-JNK 
after miR-200b knockdown. Statistical analysis was carried out using ANOVA 
with post-hoc Tukey test. Data represent the mean + SD (n=6) *p<0.05.   
 
C-D: Activation of JNK in activated BV2 microglia measured by western 
blotting using antisera against phosphorylated (p) and total JNK and quantified 
using densitometric analysis shows a decrease in phospho-JNK after miR-
200b overexpression. Statistical analysis was carried out using ANOVA with 





4.3.9 MiR-200b negatively regulates inflammatory cytokine response of 
microglia 
In order to assess the effects of miRNA-200b-mediated cJun suppression on 
microglial activation, the expression levels of proinflammatory cytokines, 
TNF-α, IL-6 and IL-1β were evaluated after miR-200b knockdown or 
overexpression.  Knockdown of miR-200b in activated BV2 microglia 
significantly increased the mRNA expression of TNF-α, IL-6 and IL-1β (Fig 
36 A-C). ELISA analysis revealed an increased TNF-α secretion in the 
medium by activated BV2 cells following miR-200b knockdown (Fig 36 D).  
In contrast, miR-200b overexpression significantly decreased the LPS-induced 
TNF-α protein secretion in the medium by BV2 microglia (Fig 36 E). 
Immunocytochemical analysis also revealed that knockdown of miR-200b 
increased the expression of TNF-α in activated microglial cells as compared to 
scrambled miR (Fig 37 Aa-Ad) whereas, miR-200b overexpression decreased 
the expression of TNF-α in activated microglia (Fig 37 Ba-Bd). Thus both 
gain- and loss-of-function studies indicate a suppressive role of miR-200b in 







Fig 36: A-C: qRT-PCR analysis of A. IL6 B. IL-1 β and C. TNFα shows an 
increase in mRNA expression after miR-200b knockdown in activated 
microglia as compared to control. Data represent the mean + SD (n=5), 
***p<0.001, **p<0.01, *p<0.05. 
 
D: TNFα protein release in media measured by ELISA shows an increase after 
miR-200b knockdown in activated BV2 microglia.   Statistical analysis was 
carried out using ANOVA with post-hoc Tukey test. Data represent the mean 
+ SD (n=5), **p<0.01, *p<0.05.  
 
E: TNFα protein release in media measured by ELISA shows a decrease after 
miR-200b overexpression in activated BV2 microglia. Statistical analysis was 
carried out using ANOVA with post-hoc Tukey test. Data represent the mean 










Fig 37 Aa-Ad: Confocal images showing the expression of TNFα (red) in 
BV2 cells transfected with scrambled probe (green) (Aa, Ab), miR-200b 
antagomir (green) (Ac, Ad), shows an increase in TNFα expression in 
activated microglia after miR-200b knockdown (Ad) as compared to 










Fig 37 Ba-Bd: Confocal images showing the expression of TNFα (red) in 
BV2 cells transfected with control mimic (Ba, Bb) and miR-200b mimic (Bc, 
Bd) shows a decrease in TNFα expression in activated microglia after miR-
200b overexpression (Bd) as compared to control mimic (Bb) (DAPI – blue) 






4.3.10 MiR-200b modulates iNOS expression and NO production in 
activated microglia 
 
The synthesis of nitric oxide (NO), an important mediator of the inflammatory 
process, is catalyzed by the inducible nitric oxide synthase (iNOS). In 
microglia, iNOS expression is induced after activation, indicating increased 
production of NO. Immunofluorescence evaluation revealed that inhibition of 
miR-200b increased iNOS expression in activated microglia (Fig 38 Aa-Ad), 
whereas downregulation of the iNOS expression was observed in activated 
microglia overexpressing miR-200b (Fig 38 Ba-Bd). Moreover, inhibition of 
miRNA-200b in activated BV2 microglia led to increased production of NO as 
compared to scrambled miR (Fig 38 C). Conversely, overexpression of miR-
200b in activated BV2 microglia significantly decreased the NO release as 
compared to control (Fig 38 D) indicating both iNOS expression and NO 















Fig 38 Aa-Ad: Confocal images showing the expression of iNOS (red) in 
BV2 cells transfected with scrambled probe (green) (Aa, Ab), miR-200b 
antagomir (green) (Ac, Ad), shows an increase in iNOS expression in 
activated microglia after miR-200b knockdown (Ad) as compared to 










Fig 38 Ba-Bd: Confocal images showing the expression of iNOS (red) in BV2 
cells transfected with control mimic (Ba, Bb) and miR-200b mimic (Bc, Bd) 
shows a decrease in iNOS expression in activated microglia after miR-200b 
overexpression (Bd) as compared to control mimic (Bb) (DAPI – blue) Scale 







Fig 38 C: Quantitative analysis of NO production using the Greiss assay 
shows an increase in NO production from activated microglia after miR-200b 
knockdown (white bars) as compared to scrambled miR (grey bars). Statistical 
analysis was carried out using ANOVA with post-hoc Tukey test. Data 
represent the mean + SD (n=4), ***p<0.001, **p<0.01, *p<0.05. 
 
Fig 38 D. Quantitative analysis of NO production using the Greiss assay 
shows a decrease in NO production from activated microglia after miR-200b 
overexpression (white bars) as compared to control mimic (grey bars). 
Statistical analysis was carried out using ANOVA with post-hoc Tukey test. 
Data represent the mean + SD (n=4), ***p<0.001, **p<0.01, *p<0.05.   
  
 
4.3.11 MiR-200b knockdown increases neuronal cell death following 
microglial activation 
 
The above results indicate that miR-200b suppresses inflammatory response of 
microglia by targeting cJun. Next we sought to determine the effect of 
modulation of miR-200b-mediated microglial immune response on neuronal 




was used in this study. Neuronal identity and dopamine production was 
confirmed by staining fully differentiated MN9D neurons with the neuronal 
marker Map2 (Fig 39 A) and Tyrosine hydroxylase (Fig 39 B). More than 2-
fold change in apoptosis was observed in neuronal cells treated with 
conditioned medium (CM) obtained from LPS-activated BV2 microglia 
transfected with scrambled miR (Fig 39 C-E). There was a further increase in 
number of apoptotic cells exposed to CM obtained from miR-200b 
knockdown BV2 microglia as compared to scrambled + LPS-treated BV2 
microglia (Fig 39 C, E). In contrast, a decrease in apoptotic neuronal cells was 
observed in culture containing CM obtained from LPS-activated microglia 
overexpressing miR-200b as compared to miR-200b knockdown BV2 


















































































































Fig 39 A-B: Confocal image of Tyrosine hydroxylase (green) (A) and Map2 
(green) (B) stained fully differentiated MN9D neuron. Arrowhead points 
towards a long axon-like projection. The nucleus is counterstained with DAPI 
(DAPI – blue). Scale bar: 20 µm. 
  
C-D: Histogram overlay representing the flow cytometric analysis of Annexin 
V fluorescence intensity indicates increased neuronal apoptosis after miR-
200b knockdown (C) as compared to miR-200b overexpression (D).  
 
E. Quantitative analysis of apoptotic MN9D cells assessed in the presence of 
microglial conditioned medium (CM) shows an increase in neuronal apoptosis 
after miR-200b knockdown (white bars). Results expressed as fold change in 
apoptotic cells with respect to control cells.  Statistical analysis was carried out 

















4.3.12 Overexpression of miRNA-200b reduces the migratory ability of 
activated microglia 
 
An important feature of activated microglia is the ability to migrate to sites of 
infection and injury. Activation of microglia by LPS results in increased 
migration as compared to untreated control (Fig 40 Ab, Bb, C, D). MiR-200b 
inhibition did not show any significant change in microglial migratory ability 
(Fig 40 Aa-Ad, C). However miR-200b overexpression significantly impaired 








Fig 40 Aa-Bd: Phase contrast images showing migrated BV2 cells (purple) 
after miR-200b inhibition (Aa-Ad) and miR-200b overexpression (Ba-Bd) in 
activated microglia. Scale bars A-D: 100 µm. 
 
C: Quantitative analysis of BV2 cell migration shows an increase in BV2 cell 
migration following activation. However miR-200b knockdown did not affect 
cell migration significantly. Statistical analysis was carried out using ANOVA 













D: Quantitative analysis of BV2 cell migration shows an increase in BV2 cell 
migration following activation. MiR-200b overexpression resulted in 
significantly impaired migration of BV2 microglia. Statistical analysis was 
carried out using ANOVA with post-hoc Tukey test. Data represent the mean 























5.1 Activated microglia display distinct miRNA profile 
Microglia, the immune cells of the central nervous system, protect the brain 
parenchyma against various insults via several effector functions such as 
secretion of proinflammatory cytokines, chemokines, cytotoxic factors as well 
as phagocytosis of cellular debris. However during an excessive microgliosis 
in response to chronic neuropathological conditions such as  
neuroinflammation or neurodegeneration, microglia secrete proinflammatory 
cytokines and cytotoxic factors excessively, exacerbating neuronal cell death 
(Dheen et al. 2007). Thus, there is a need for optimization of microglial 
functions to control microglia-mediated neuroinflammation. Recently, 
miRNAs have been shown to be involved in regulating microglia behavior and 
functions in diverse CNS pathologies including stroke, ischemic brain injuries 
(Selvamani et al. 2012; Zhao et al. 2013), multiple sclerosis (Ponomarev et al. 
2011), and prion disease (Saba et al. 2012), by targeting numerous genes. 
However, a comprehensive catalogue showing the changes in miRNA 
expression in activated microglia is lacking. Towards this end, we carried out 
a microarray of microRNA expression profile and identified several 
differentially expressed miRNAs in activated microglia. Some miRNAs such 
as miR-21 and the miR-29 family identified in the microarray, have already 
been established to play a role in microglia-mediated neuroinflammation 
(Zhang et al. 2012; Thounaojam et al. 2014). Several other miRNAs such 
miR-101, miR-27a, also among the top hits obtained in the miRNA microarray 




macrophages, but their function in microglia remains to be elucidated (Zhu et 
al. 2010; Xie et al. 2014). 
 
5.2 MiR-27a regulates the TGF-SMAD signaling pathway in 
microglia 
 
5.2.1 MiR-27a is upregulated in activated microglia 
In the current study, miR-27a expression was observed to be upregulated in 
activated primary microglia in vitro as well as in vivo (in activated microglial 
cells isolated from TBI model). Previosly, miR-27a upregulation was reported 
in peripheral macrophages activated with M1 (LPS + IFN) and M2b (LPS + 
Fc receptor) stimuli, indicating its role in peripheral macrophage 
differentiation toward distinct activation patterns (Graff et al. 2012). 
Additionally, the expression of miR-27b, a close homolog of miR-27a (20/21 
nucleotide identity), has been shown to be upregulated 2.3 fold in response to 
LPS in human primary macrophages (Jennewein et al. 2010).  These results 
suggest that upregulation of miR-27a in the present study, is associated with 
activation of microglia and may regulate the expression of genes involved in 
the inflammatory response of microglia. 
 
5.2.2 MiR-27a targets key members of the TGF signaling pathway in 
microglia 
In microglia, LPS which promotes proinflammation and TGFβ which is anti-




study, key regulators of the TGFβ1 signaling pathway, SMAD2 and TβR1 
were observed to be downregulated, in activated microglia.  Loss-of-function 
and gain-of-function studies confirmed that miR-27a targets TGFβ1 signaling 
pathway molecules including SMAD2 and TβR1 as shown in colon cancer 
where miR-27a interacts with the 3’UTR of SMAD2 (Bao et al. 2014). 
Although several miRNAs such as miR-140-5p (Yang et al. 2013), miR-142-
3p (Lei et al. 2014) have been reported to target TβR1,  this is the first report 
demonstrating TβR1 as a novel target of miR-27a in microglia.  
TGFβ promotes SMAD2 activation by phosphorylation (Massagué 
2000; Khalil et al. 2001). This SMAD2 phosphorylation was found to be 
increased in TGFβ activated microglia after knockdown of miR-27a, 
suggesting that SMAD2 expression and function are regulated by miR-27a in 
microglia.  However, further study is required as the overexpression of miR-
27a did not reduce the phosphorylation of SMAD2 significantly. 
Runx1 is an important component of the TGFβ superfamily (Ito and 
Miyazono 2003) and has been shown to control microglial proliferation and 
activation in the rat brain after TBI (Logan et al. 2013). Further, Runx1 has 
also been shown to inhibit microglial proliferation and help promote the 
progression of amoeboid microglia to the ramified state (Zusso et al. 2012). 
Taken together these reports suggest that Runx1 is upregulated in activated 
microglia to control microglial activation possibly via inhibition of microglial 
proliferation. In this study, Runx1 expression was observed to be upregulated 
in LPS and TGFβ activated primary microglia in vitro as well as in vivo in 
LCM-extracted activated microglia cells from TBI rat model. Further, Runx1 




reports (Ben-Ami et al. 2009; Feng et al. 2009).Thus, in the current study, it is 
possible that Runx1 is upregulated in TGFβ activated microglia to control 
microglial activation. However, miR-27a alters Runx1 expression thereby 
inhibiting TGFβ signaling in activated microglia.  
 
5.2.3 MiR-27a regulates the inflammatory response of microglia 
In activated microglia, in response to various stimuli, such as infection, injury 
or neurodegeneration, excessive release of proinflammatory mediators such as 
TNFα, IL6, IL-1β,  and NO has been shown to be mediated by the 
transcription factor, NFκB (Collart et al. 1990; Zielasek and Hartung 1996; 
Ghosh et al. 1998).  In the current study, overexpression of miR-27a enhanced 
the proinflammatory response of activated microglia, as evidenced by 
increased expression of the proinflammatory cytokines, increased nuclear 
translocation of NFκB and downregulation of the alternate activation genes 
Arginase1 and Ym1. This enhanced proinflammatory response could be due to 
the result of inhibition of anti-inflammatory TGFβ signaling pathway by miR-
27a in microglia via reduction of its mediators SMAD2 and TβR1. However, it 
needs to be ascertained if miR-27a directly acts on NFκB signaling pathway. 
 
Moreover, mounting evidence suggests that miRNAs (such as miR-155 
and miR-124) can regulate the polarization of peripheral macrophages and 
microglia towards M1 or M2 phenotype (Louafi et al. 2010; Martinez-Nunez 
et al. 2011; Ponomarev et al. 2011). By suppressing TGFβ signaling members, 
miR-27a appears to promote the polarization of microglia towards the M1 




number of alternate activation genes, need to be performed, to ascertain the 
same. 
 
5.2.4 MiR-27a knockdown in microglia increases neuronal survival 
TGF is an anti-inflammatory cytokine that functions as an 
immunomodulatory molecule to limit the potentially injurious effects of 
sustained or excess inflammatory reaction of microglia in the CNS (Lodge 
1996; Kim, Won-Ki et al. 2004; Spittau et al. 2013). Overexpression or 
injection of TGFβ1 in the CNS suppresses microglial activation thereby 
limiting the expression proinflammatory chemokines after hypoxic/ischemic 
injury (Gross et al. 1993). In mixed glial cultures, microglia are the main 
source of TGFβ (Welser-Alves and Milner 2013), which is produced to inhibit 
the production of proinflammatory cytokines (Chao and Peterson 1995; Lodge 
1996) and reactive oxygen intermediates. It has been postulated that low level 
of constitutively expressed TGF contributes to homeostasis of the healthy 
brain. Our studies on neuronal apoptosis after treatment with microglial 
conditioned medium suggest that miR-27a overexpression increases microglia-
mediated neurotoxic effect. This observed increase in neuronal apoptosis in 
the culture exposed to conditioned medium derived from microglia after miR-
27a overexpression, is most probably due to the result of an excessive release 
of proinflammatory cytokines in the conditioned medium, mediated via 
suppression of TGFβ signaling mediators. On the other hand, miR-27a 
knockdown decreases microglia-mediated neurotoxic effect possibly by 




medium. Overall, our results demonstrate that miR-27a knockdown is able to 
decrease microglia-mediated neurotoxicity and may, thus, represent a valuable 
therapeutic strategy in the context of chronic inflammation. 
 
5.3 Mir-200b regulates the cJun/MAPK pathway in microglia 
 
5.3.1 MiR-200b is downregulated in activated microglia 
MicroRNA-200b (miR-200b) belongs to a family of five miRNAs with 
overlapping functions (Pecot et al. 2013). MiR-200b and miR-200c have been 
shown to regulate antibacterial innate immune response by targeting the TLR4 
signaling pathway (Wendlandt et al. 2012). Further, miR-200c was found to 
be expressed in microglia, indicating a role for this family of miRNAs in 
regulating microglial functions in the CNS (Jovičić et al. 2013). The present 
work provides evidence, for the first time, that miR-200b is expressed in 
microglial cells and its expression is significantly down-regulated in activated 
microglial cells in vitro and in vivo model of TBI. 
5.3.2 MiR-200b targets cJun in microglia 
cJun, a member of the MAPK pathway, is activated in response to a number of 
stimuli in microglia in vitro (Kim et al. 2004; Waetzig et al. 2005) as well as 
in a number of neuropathologies in vivo such as brain injury (Pennypacker 
1997), multiple sclerosis (Bonetti et al. 1999). An addition to this data is our 
result demonstrating the upregulation of cJun expression activated microglia 




MAPKs have been shown to play critical roles in the pathogenesis of 
many neurological disorders, including ischemic stroke (Kuan et al. 2003), 
Parkinson’s disease (PD) (Chipuk et al. 2008; Klegeris et al. 2008), 
amyotrophic lateral sclerosis (Bendotti et al. 2005) and Alzheimer’s disease 
(AD) (Tamagno et al. 2003, 2005; Colombo et al. 2009). Thus inhibitors of 
MAPK pathways are being explored as potential therapeutic targets for 
ameliorating neuroinflammation in CNS pathologies (Cui et al. 2007). This 
current study has established miR-200b, a novel epigenetic factor as regulating 
cJun, a transcription factor of the JNK-MAPK pathway, in microglia, by 
directly targeting its 3’UTR. This is the first report demonstrating cJun as a 
novel target of miR-200b in microglia. 
cJun function is activated by phosphorylation, which is mediated by 
JNK (Pulverer et al. 1991; Hibi et al. 1993). This cJun phosphorylation was 
found to be significantly increased in activated microglia after miR-200b 
knockdown and decreased after miR-200b overexpression, suggesting that 
miR-200b targets cJun and alters its expression and function in microglia. 
 
5.3.3 MiR-200b negatively regulates the inflammatory response in 
microglia 
JNK signaling in MAPK pathway plays a predominant role in secretion of 
proinflammatory cytokines and chemokines in activated primary microglia by 
LPS (Waetzig et al. 2005), while all three MAPK cascades (ERK, JNK and 
p38) are activated in BV2 microglia in response to LPS stimulation (Kim et al. 
2004). In the present study, suppression of JNK activity in microglia by 




and function, suggesting a dysregulation of the JNK pathway in microglia. 
Further, the observed significant suppression of cytokine production as well as 
iNOS expression and NO production, by ovreexpression of miR-200b in 
microglia, might result from the miR-200b caused attenuation of cJun/JNK 
signaling.  
 
5.3.4 MiR-200b knockdown in microglia increases neurotoxicity 
Multiple lines of evidence suggests that chronic activation of microglia 
exacerbates the neuronal damage in different CNS pathologies (Tuppo and 
Arias 2005; Phani et al. 2012; Rubio-Perez and Morillas-Ruiz 2012). Findings 
in the present study suggest that inhibition of miR-200b increases microglia-
mediated neurotoxic effect. This observed increase in neuronal apoptosis in 
the culture exposed to conditioned medium derived from culture of microglia 
treated with miR-200b inhibitor, is most probably due to the result of an 
excessive release of proinflammatory cytokines and NO in the conditioned 
medium mediated via increased cJun activity. However, further experiments 
are required to ascertain the possible neuroprotective role of microglial miR-
200b since the overexpression of miR-200b in microglia failed to overcome 
the LPS-mediated neuronal apoptosis. 
 
5.3.5 MiR-200b overexpression impairs microglial migration 
It has been well established that activated microglia proliferate and migrate to 
the site of injury and infection for defense. Impaired microglial migration has 
been shown to contribute to the pathogenesis of several neuropathologies 




demonstrate that overexpression of miR-200b in activated microglia results in 
impaired migration. While it is unclear whether these observations are a result 
of a direct inhibition of cJun activity and its subsequent downstream targets or 
via targeting of other mRNA factors, this study provides a link between 





The smallest of the glial cells, microglia, is one cell with many functions from 
immune surveillance to neurogenesis (Nayak et al. 2014). The remarkable 
plasticity of these cells enables them to execute such a myriad variety of 
functions with ease. Morphologically and functionally, microglia are classified 
as postnatal/amoeboid, resting/ramified and activated (Ling and Wong 1993). 
Upon encountering any CNS insult, microglia undergo morphological changes 
and molecular and epigenetic transformation to become activated, 
accompanied by release of proinflammatory cytokines, chemokines, proteases 
and cytotoxic molecules such as NO and ROS (Aloisi 2001). Furthermore, 
chronic activation of microglia leads to excessive release of proinflammatory 
mediators, exaggerating the neuronal death in several neuropathologies such 
as neurodegenerative diseases, injury and infection. Thus, it is important to 
understand the molecular and epigenetic mechanisms underlying microglial 
activation, to develop therapeutics to control microglial mediated 




the molecular changes accompanying this transformation are well 
documented, the epigenetic changes such as histone modifications and 
miRNAs need to be examined in detail. 
 To address this gap in literature, a miRNA microarray comparing 
control and activated primary microglia was carried out in the present study 
which established a database of differentially expressed miRNAs in microglia. 
Two miRNAs were chosen for their putative proinflammatory (miR-27a, since 
it was upregulated in activated microglia) and anti-inflammatory (miR-200b 
since its expression was decreased in activated microglia) potential. These 
miRNAs were shown to target pathways either bringing about microglial 
quiescence (TGFβ) or in aiding the inflammatory cascade (MAPK), in 
microglia. 
 To conclude, two in vitro mechanisms of miRNA mediated regulation 
of microglial functions including inflammatory response, migration and 







Illustration 6: Epigenetic mechanism of microglial-mediated 
neuroinflammation. There was a downregulation of miR-200b and in contrast, 
upregulation of miR-27a in microglia activated by LPS. MiR-200b targets 
cJun and thus the downregulation of miR-200b in activated microglia 
enhances the expression of cJun, which subsequently contributes to 
upregulation of proinflammatory mediators (TNF-α, IL6, iNOS) and 
neurotoxicity. On the other hand, miR-27a targets TGF-β signaling and its 
upregulation in activated microglia, downregulates the anti-inflammatory 









5.5 FUTURE DIRECTIONS 
Post-transcriptional reduction of protein expression of selected genes linked to 
a disease by a particular functional miRNA represents new therapeutic 
options. The current study identifies two miRNAs in microglia having 
therapeutic potential and focuses on the in vitro mechanism of miRNA 
mediated regulation of microglial neuroinflammation.  
To elucidate the therapeutic potential of the miRNAs under 
consideration, it is important to study their mechanism of action in vivo in an 
animal model of neuropathy such as traumatic brain injury or stroke. This can 
be achieved by administration of the miRNA mimic or miRNA inhibitor 
intracranially. However, since the miRNA mimic/inhibitor would not be 
targeted towards a particular cell type, such analysis would only provide 
information on the general effect of the overexpression/knockdown of the 
specific miRNA under consideration, on the disease condition in vivo. 
Further studies can also include specifically targeting microglia in vivo 
by exploiting the presence of CX3CR1 receptor which is solely expressed by 
microglia in the brain and using synthetic delivery materials such as liposomes 
(Zhang et al. 2013). 
It has been seen that injection of miR-124 in the brain has the potential 
to reduce EAE (Ponomarev et al. 2011). Further, knockdown of another brain 
enriched miRNA, miR-181, could provide protection against ischemia induced 




outcome of cerebral ischemia (Ouyang et al. 2012). Taken together, these 
results suggest that in vivo administration of miRNA inhibitors or mimics 
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1 rno-miR-101a-3p 1.66E-03 
2 rno-miR-101b-3p 1.66E-03 
3 rno-miR-19a-3p 1.66E-03 
4 rno-miR-20b-5p 1.66E-03 
5 rno-miR-21-5p 1.66E-03 
6 rno-miR-291a-5p 1.66E-03 
7 rno-miR-29a-5p 1.66E-03 
8 rno-miR-29b-3p 1.66E-03 
9 rno-miR-29c-3p 1.66E-03 
10 rno-miR-30e-5p 1.66E-03 
11 rno-miR-485-3p 1.66E-03 
12 rno-miR-19b-3p 1.90E-03 
13 rno-miR-27a-3p 1.90E-03 
14 rno-miR-30a-5p 1.90E-03 
15 rno-miR-370-5p 1.90E-03 
16 rno-miR-664-1-5p 1.90E-03 
17 rno-let-7i-5p 1.93E-03 
18 rno-miR-294 1.93E-03 
19 rno-miR-374-3p 3.87E-03 




21 rno-miR-106b-5p 6.95E-03 
22 rno-miR-20a-5p 6.95E-03 
23 rno-miR-26b-5p 6.95E-03 
24 rno-miR-140-5p 7.36E-03 
25 rno-miR-148b-3p 7.36E-03 
26 rno-miR-195-5p 7.36E-03 
27 rno-miR-24-2-5p 7.36E-03 
28 rno-miR-29a-3p 7.36E-03 
29 rno-miR-328b-3p 7.36E-03 
30 rno-miR-3559-5p 7.36E-03 
31 SNORD110 7.36E-03 
32 rno-miR-883-5p 7.47E-03 
33 rno-miR-142-3p 8.07E-03 
34 rno-miR-34a-5p 9.39E-03 
35 rno-miR-1949 9.57E-03 
36 rno-miR-16-5p 1.03E-02 
37 rno-miR-301a-3p 1.03E-02 
38 rno-miR-328a-3p 1.10E-02 
39 rno-miR-466b-5p 1.15E-02 
40 rno-miR-142-5p 1.15E-02 
41 rno-miR-27b-3p 1.25E-02 
42 rno-miR-30b-5p 1.25E-02 
43 rno-miR-350 1.25E-02 




45 rno-miR-465-5p 1.25E-02 
46 rno-miR-493-5p 1.25E-02 
47 rno-miR-181b-5p 1.27E-02 
48 rno-miR-3559-3p 1.27E-02 
49 SNORD65 1.28E-02 
50 rno-miR-17-5p 1.34E-02 
51 rno-miR-300-5p 1.39E-02 
52 rno-miR-9a-3p 1.39E-02 
53 SNORD12 1.39E-02 
54 SNORD3@ 1.39E-02 
55 rno-miR-9a-5p 1.44E-02 
56 rno-miR-347 1.46E-02 
57 rno-miR-449a-5p 1.47E-02 
58 rno-miR-339-5p 1.48E-02 
59 rno-miR-338-3p 1.67E-02 
60 rno-miR-107-3p 1.68E-02 
61 rno-miR-190a-5p 1.68E-02 
62 rno-miR-423-5p 1.74E-02 
63 rno-miR-214-3p 1.74E-02 
64 rno-let-7f-5p 2.32E-02 
65 rno-miR-1843-3p 2.32E-02 
66 SNORD2 2.52E-02 
67 rno-miR-30d-5p 2.57E-02 




69 rno-miR-299a-5p 2.91E-02 
70 rno-miR-331-3p 2.91E-02 
71 rno-miR-3568 2.94E-02 
72 rno-miR-466c-5p 2.94E-02 
73 rno-miR-30e-3p 3.02E-02 
74 rno-miR-665 3.08E-02 
75 rno-miR-3580-3p 3.09E-02 
76 rno-miR-872-5p 3.09E-02 
77 SNORD6 3.09E-02 
78 rno-miR-21-3p 3.20E-02 
79 rno-let-7d-3p 3.30E-02 
80 rno-miR-503-5p 3.57E-02 
81 rno-miR-22-3p 3.58E-02 
82 rno-miR-181a-5p 3.66E-02 
83 rno-miR-466d 3.66E-02 
84 rno-miR-9b-5p 3.66E-02 
85 rno-miR-26a-5p 3.75E-02 
86 rno-miR-30c-5p 3.78E-02 
87 rno-miR-150-5p 3.85E-02 
88 rno-miR-500-3p 3.85E-02 








92 rno-miR-34c-5p 4.39E-02 






7.2 Sheet 2: Top 63 miRNAs (p<0.05) differentially expressed 
between control and LPS activated primary microglia. 
No miRNA logFC p-value 
1 rno-miR-29b-3p 1.785 1.54E-04 
2 rno-miR-101a-3p 1.362 2.20E-04 
3 rno-miR-29c-3p 1.290 2.20E-04 
4 rno-miR-30e-5p 1.194 2.20E-04 
5 rno-miR-101b-3p 1.109 2.86E-04 
6 rno-miR-20b-5p 0.913 2.86E-04 
7 rno-miR-142-5p 1.802 4.08E-04 
8 rno-miR-21-5p 1.072 4.08E-04 
9 rno-miR-27a-3p 1.003 4.08E-04 
10 rno-miR-30a-5p 0.920 4.08E-04 
11 rno-miR-339-5p 1.083 4.08E-04 
12 rno-miR-19a-3p 0.918 4.66E-04 
13 rno-miR-19b-3p 1.004 4.68E-04 
14 rno-miR-142-3p 2.425 6.76E-04 
15 rno-miR-370-5p 0.964 7.73E-04 
16 rno-miR-34a-5p 1.135 9.28E-04 
17 rno-miR-20a-5p 0.908 1.25E-03 
18 rno-miR-29a-5p 0.553 1.65E-03 
19 rno-let-7i-5p 0.594 1.81E-03 




21 rno-miR-24-2-5p 0.788 2.19E-03 
22 rno-miR-29a-3p 0.764 2.19E-03 
23 rno-miR-106b-5p 0.822 2.25E-03 
24 rno-miR-16-5p 0.648 2.25E-03 
25 rno-miR-30b-5p 0.686 2.75E-03 
26 rno-miR-140-5p 0.641 3.04E-03 
27 rno-miR-9a-5p 1.173 3.07E-03 
28 rno-miR-214-3p -1.291 3.61E-03 
29 rno-miR-301a-3p 0.715 4.03E-03 
30 rno-miR-9a-3p 0.925 4.55E-03 
31 rno-miR-27b-3p 0.603 6.19E-03 
32 rno-miR-26b-5p 0.491 6.39E-03 
33 rno-miR-146a-5p 1.541 6.74E-03 
34 rno-miR-195-5p 0.500 7.37E-03 
35 rno-miR-493-5p -0.441 7.37E-03 
36 rno-miR-449a-5p 1.044 7.83E-03 
37 rno-miR-190a-5p 0.626 8.39E-03 
38 rno-miR-30d-5p 0.537 8.39E-03 
39 rno-miR-3559-5p -0.402 8.39E-03 
40 rno-miR-34c-5p 0.490 8.83E-03 
41 rno-miR-148b-3p 0.396 1.00E-02 
42 rno-miR-338-3p 0.638 1.25E-02 
43 rno-miR-146b-5p 1.255 1.31E-02 






45 rno-miR-33-5p 0.765 1.35E-02 
46 rno-miR-145-5p -0.698 1.40E-02 
47 rno-miR-350 0.365 1.40E-02 
48 rno-miR-21-3p 0.628 1.51E-02 
49 rno-miR-291a-5p 0.419 1.66E-02 
50 rno-miR-30c-5p 0.505 1.66E-02 
51 rno-miR-664-1-5p -0.342 1.78E-02 
52 rno-miR-150-5p -0.707 1.93E-02 
53 rno-miR-1949 -0.353 1.93E-02 
54 rno-miR-99b-5p -0.775 2.06E-02 
55 rno-miR-365-3p -0.456 2.73E-02 
56 rno-miR-34b-5p 0.566 2.89E-02 
57 rno-miR-9b-5p 0.491 3.78E-02 
58 rno-miR-872-5p 0.352 3.84E-02 
59 rno-miR-107-3p 0.299 3.85E-02 
60 rno-miR-199a-3p -0.646 3.85E-02 
61 rno-miR-351-5p -0.307 3.85E-02 
62 rno-miR-22-3p 0.369 3.86E-02 




7.3 Sheet 3: Top 63 miRNAs (p<0.05) differentially expressed 
between control and Aβ activated primary microglia. 
No miRNA logFC p-value 
1 rno-miR-21-5p 1.022 1.15E-03 
2 rno-miR-485-3p 1.561 1.16E-03 
3 rno-miR-370-5p 0.902 1.35E-03 
4 rno-miR-291a-5p 0.826 1.59E-03 
5 rno-miR-101b-3p 0.664 2.96E-03 
6 rno-miR-30e-5p 0.684 2.96E-03 
7 rno-miR-29b-3p 1.113 2.96E-03 
8 rno-miR-27a-3p 0.733 2.96E-03 
9 rno-miR-101a-3p 0.768 3.89E-03 
10 rno-miR-301a-3p 0.648 4.24E-03 
11 rno-miR-106b-5p 0.558 4.69E-03 
12 rno-miR-300-5p 0.946 5.24E-03 
13 rno-miR-664-1-5p -0.420 5.24E-03 
14 rno-miR-374-3p 0.666 5.93E-03 
15 rno-miR-294 0.586 5.93E-03 
16 rno-miR-19a-3p 0.622 5.93E-03 
17 rno-miR-29c-3p 0.631 9.59E-03 
18 rno-miR-3592 -0.374 1.03E-02 
19 rno-miR-143-3p 0.592 1.30E-02 




21 rno-miR-19b-3p 0.610 1.52E-02 
22 rno-miR-883-5p 0.498 1.52E-02 
23 rno-miR-24-2-5p 0.485 1.57E-02 
24 rno-miR-465-5p -0.355 1.60E-02 
25 rno-let-7b-5p -0.559 1.77E-02 
26 rno-miR-3559-3p 1.039 1.86E-02 
27 rno-miR-328a-3p -0.314 2.17E-02 
28 rno-miR-29a-3p 0.440 2.17E-02 
29 rno-miR-1843-3p -0.362 2.17E-02 
30 SNORD110 -0.335 2.23E-02 
31 rno-miR-20a-5p 0.560 2.23E-02 
32 rno-miR-193-3p 0.634 2.23E-02 
33 rno-miR-3568 -0.327 2.62E-02 
34 rno-miR-30a-5p 0.445 2.81E-02 
35 rno-miR-328b-3p -0.285 2.81E-02 
36 rno-miR-503-5p 0.342 2.92E-02 
37 rno-miR-34a-5p 0.699 3.21E-02 
38 rno-miR-34b-3p -0.357 3.26E-02 
39 rno-miR-22-3p 0.334 3.26E-02 
40 rno-miR-33-5p 0.440 3.26E-02 
41 SNORD2 -0.307 3.26E-02 
42 rno-miR-204-3p 0.700 3.26E-02 
43 rno-miR-3068-3p -0.344 3.26E-02 




45 SNORD65 -0.272 3.26E-02 
46 rno-miR-466b-5p -0.293 3.26E-02 
47 rno-miR-92a-3p -0.324 3.26E-02 
48 rno-let-7i-5p 0.278 3.26E-02 
49 SNORD12 -0.263 3.26E-02 
50 rno-miR-181b-5p -0.292 3.26E-02 
51 SNORD6 -0.257 3.26E-02 
52 rno-miR-1949 -0.304 3.26E-02 
53 rno-let-7c-5p -0.436 3.26E-02 
54 rno-miR-493-5p -0.363 3.26E-02 
55 rno-miR-125a-5p -0.483 3.31E-02 
56 rno-miR-27b-3p 0.405 3.34E-02 






59 rno-miR-347 -0.279 3.39E-02 
60 rno-miR-466d -0.341 3.44E-02 
61 rno-miR-16-5p -0.261 3.44E-02 
62 rno-let-7d-5p 0.356 3.71E-02 






7.4 Sheet 4: Top 33 miRNAs with p<0.05 differentially 
expressed between LPS and Aβ activated primary 
microglia.   
No miRNA logFC p-value 
1 rno-miR-3559-3p 1.152 1.41E-04 
2 rno-miR-485-3p 1.471 1.79E-03 
3 rno-miR-294 0.606 2.21E-03 
4 rno-miR-3596c 0.507 1.01E-02 
5 rno-miR-883-5p 0.646 1.01E-02 
6 rno-miR-374-3p 0.596 1.08E-02 
7 rno-miR-210-5p 0.771 2.62E-02 
8 rno-miR-449a-5p -1.109 3.24E-02 
9 rno-miR-291a-5p 0.407 3.24E-02 
10 rno-miR-195-5p -0.445 3.24E-02 
11 SNORD3@ 0.463 3.24E-02 
12 rno-miR-30e-5p -0.510 3.24E-02 
13 rno-miR-3573-3p 0.352 3.24E-02 
14 rno-miR-142-3p -1.230 3.24E-02 
15 rno-miR-665 0.348 3.41E-02 
16 rno-miR-30a-5p -0.474 3.41E-02 
17 rno-miR-29c-3p -0.658 3.41E-02 
18 rno-miR-351-5p 0.315 3.41E-02 




20 rno-miR-300-5p 0.617 3.44E-02 
21 rno-miR-19b-3p -0.394 3.44E-02 
22 rno-miR-140-5p -0.377 3.86E-02 
23 rno-miR-101b-3p -0.445 4.42E-02 
24 rno-miR-9b-5p -0.452 4.42E-02 
25 rno-miR-101a-3p -0.594 4.42E-02 
26 rno-miR-9a-5p -0.756 4.42E-02 
27 rno-miR-142-5p -1.103 4.42E-02 
28 rno-miR-500-3p -0.261 4.42E-02 
29 rno-miR-148b-3p -0.265 4.42E-02 
30 rno-miR-9a-3p -0.627 4.49E-02 
31 rno-miR-29b-3p -0.672 4.58E-02 
32 rno-miR-675-5p 0.352 4.78E-02 





7.5 Sheet 5: Common miRNAs significantly upregulated in 





No miRNA logFC (LPS) logFC (amyloid β) 
1 rno-miR-29b-3p  1.785  1.113  
2 rno-miR-29c-3p  1.29  .631  
3 rno-miR-29a-3p  .764  .44  
4 rno-miR-101a-3p  1.362  .768  
5 rno-miR-101b-3p  1.109  .664  
6 rno-miR-21-5p  1.072  1.022  
7 rno-miR-30e-5p  1.194  .684  
8 rno-miR-20b-3p  .913  .515  
9 rno-miR-19a-3p  .918  .622  
10 rno-miR-19b-3p  1.004  .61  
11 rno-miR-24-2-5p  .788  .485  
12 rno-miR-106b-5p  .822  .558  
13 rno-miR-301a-3p  .715  .648  




7.6 Sheet 6: MiRNAs targeting genes from the TGFβ pathway 
as obtained from Ingenuity pathway analysis software.  
 
No miRNA Gene 
1 rno-miR-101a-3p ACVR1C 
2 rno-miR-101a-3p ACVR2B 
3 rno-miR-101a-3p BMPR1B 
4 rno-miR-101a-3p FOS 
5 rno-miR-101a-3p MAPK1 
6 rno-miR-101a-3p SMAD2 
7 rno-miR-101a-3p TGFBR1 
8 rno-miR-101a-3p TGIF1 
9 rno-miR-20b-5p ACVR1B 
10 rno-miR-20b-5p BCL2 
11 rno-miR-20b-5p BMP2 
12 rno-miR-20b-5p BMPR2 
13 rno-miR-20b-5p MAPK1 
14 rno-miR-20b-5p MAPK9 
15 rno-miR-20b-5p RUNX3 
16 rno-miR-20b-5p SKI 
17 rno-miR-20b-5p SMAD4 
18 rno-miR-20b-5p SMAD5 




20 rno-miR-20b-5p SMAD7 
21 rno-miR-20b-5p SMURF1 
22 rno-miR-20b-5p SOS1 
23 rno-miR-20b-5p TGFBR2 
24 rno-miR-20b-5p ZFYVE9 
25 rno-miR-21-5p ACVR1C 
26 rno-miR-21-5p ACVR2A 
27 rno-miR-21-5p BCL2 
28 rno-miR-21-5p BMPR2 
29 rno-miR-21-5p MAP2K3 
30 rno-miR-21-5p PITX2 
31 rno-miR-21-5p SKI 
32 rno-miR-21-5p SMAD7 
33 rno-miR-21-5p TGFB2 
34 rno-miR-21-5p TGFBR2 
35 rno-miR-27a-3p ACVR1C 
36 rno-miR-27a-3p ACVR2A 
37 rno-miR-27a-3p ACVR2B 
38 rno-miR-27a-3p BMPR1A 
39 rno-miR-27a-3p GRB2 
40 rno-miR-27a-3p KRAS 
41 rno-miR-27a-3p MAP2K4 
42 rno-miR-27a-3p MAPK14 




44 rno-miR-27a-3p RNF111 
45 rno-miR-27a-3p SMAD2 
46 rno-miR-27a-3p SMAD3 
47 rno-miR-27a-3p SMAD4 
48 rno-miR-27a-3p SMAD5 
49 rno-miR-27a-3p SMAD9 
50 rno-miR-27a-3p SOS1 
51 rno-miR-27a-3p TGFBR1 
52 rno-miR-29b-3p ACVR2A 
53 rno-miR-29b-3p CDC42 
54 rno-miR-29b-3p FOS 
55 rno-miR-29b-3p MAP2K4 
56 rno-miR-29b-3p MAP2K6 
57 rno-miR-29b-3p NRAS 
58 rno-miR-29b-3p PIAS4 
59 rno-miR-29b-3p SKI 
60 rno-miR-29b-3p TGFB2 
61 rno-miR-29b-3p TGFB3 
62 rno-miR-30e-5p ACVR1 
63 rno-miR-30e-5p BCL2 
64 rno-miR-30e-5p BMP7 
65 rno-miR-30e-5p JUN 
66 rno-miR-30e-5p KRAS 




68 rno-miR-30e-5p SERPINE1 
69 rno-miR-30e-5p SMAD1 
70 rno-miR-30e-5p SMAD2 
71 rno-miR-30e-5p SOS1 
 
 
 
 
 
 
 
 
 
 
 
 
